The Weekly Term Sheet (2026-W12)
The week of March 15-21, 2026, marked a notable tempo change in the global life sciences deal landscape. After a blistering W11 that saw over $3.8 billion in new capital raised across biotech equity and convertible offerings, the opening days of W12 were dominated not by headline-grabbing M&A but by four concurrent global conferences—NVIDIA GTC in San Jose, the European Association of Urology (EAU) congress in London, the Alzheimer's and Parkinson's Disease (AD/PD) conference in Copenhagen, and the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels—that collectively shaped the week's deal and data narratives.
Yet beneath the conference-driven surface, the week was substantially busier than it first appeared—and its final two days delivered the marquee M&A that earlier sessions had lacked. On Friday, Novartis agreed to acquire Pikavation Therapeutics from Synnovation for $2 billion upfront plus up to $1 billion in milestones—the week's single largest transaction. Collegium Pharmaceutical struck a $650 million cash deal (plus $135 million in milestones) for Corium's AZSTARYS ADHD franchise.
And Zenas BioPharma secured a $250 million pre-commercial debt facility from Pharmakon Advisors ahead of its obexelimab BLA filing.
The FDA approved Johnson & Johnson's ICOTYDE (icotrokinra)—the first-in-class oral IL-23 receptor antagonist for plaque psoriasis, triggering a $50 million milestone payment to Protagonist Therapeutics and activating a 6-10% royalty stream on what analysts project as a $5-10 billion peak-sales franchise. The FDA approved Novo Nordisk's Wegovy HD (semaglutide 7.2 mg)—the highest-dose GLP-1 injection ever approved, delivering 20.7% mean weight loss—in just 54 days under the Commissioner's National Priority Voucher pilot program, and GSK's Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis.
Eli Lilly reported positive Phase 3 TRANSCEND-T2D-1 results for retatrutide, its first-in-class GIP/GLP-1/glucagon triple agonist, showing up to 2.0% A1C reduction and 16.8% weight loss in type 2 diabetes—the first Phase 3 readout for this next-generation metabolic drug. Pfizer delivered a pair of practice-changing clinical datasets: positive Phase 2 data for its next-generation CDK4 inhibitor atirmociclib in breast cancer (40% risk reduction, p=0.0007), and positive Phase 3 TALAPRO-3 results showing that Talzenna (talazoparib) plus Xtandi (enzalutamide) significantly improved radiographic progression-free survival in HRR gene-mutated metastatic castration-sensitive prostate cancer—the first PARP inhibitor Phase 3 success in this earlier disease setting.
Structure Therapeutics delivered 16.3% placebo-adjusted weight loss at 44 weeks with its oral GLP-1 agonist aleniglipron, and Bayer's KERENDIA (finerenone) met the primary endpoint in FIND-CKD—potentially doubling its addressable CKD market to include non-diabetic patients.
On the setback side, Rhythm Pharmaceuticals' Imcivree failed all four substudies of the Phase 3 EMANATE trial in rare MC4R pathway diseases, Roche discontinued emugrobart in both spinal muscular atrophy (MANATEE Phase 2/3) and facioscapulohumeral muscular dystrophy (MANOEUVRE Phase 2) after the anti-myostatin antibody failed to demonstrate consistent improvements in muscle growth
BioMarin suspended three Voxzogo Phase 2 trials after slipped capital femoral epiphysis safety signals
Roche/Genentech terminated its RIPK1 inhibitor flizasertib in acute kidney injury after a Phase 2 futility analysis
Aldeyra's reproxalap received its third Complete Response Letter—dashing hopes for a $100 million AbbVie milestone.
CytomX Therapeutics priced a $250 million underwritten public offering (Jefferies, Piper Sandler, Cantor, Barclays as joint book-runners) to fund its proprietary Varseta-M pipeline in the same week that Astellas terminated their $1.6 billion collaboration.
Crossbow Therapeutics closed a $77 million Series B (co-led by Taiho Ventures and Arkin Bio Capital) to advance TCR-mimetic T-cell engager therapies.
ProLynx raised a $70 million Series A for longer-acting obesity drugs, and Excalipoint Therapeutics launched with a $68.7 million seed—one of the largest in Chinese biotech history—for next-generation T-cell engager platforms.
Sandoz and Samsung Bioepis expanded their biosimilar partnership to cover up to five next-generation candidates including a vedolizumab biosimilar.
CRISPR Therapeutics closed a $600 million convertible note offering, Blackstone led a $1.3 billion debt financing for the Paratek-Radius Health combination (creating a ~$1 billion revenue specialty pharma platform)
Blue Owl Capital extended a $750 million senior secured credit facility to TG Therapeutics (netting $500 million in new non-dilutive capital for the BRIUMVI franchise),
QHP Capital closed a $1.1 billion GP-led continuation vehicle for Azurity Pharmaceuticals (the largest single-asset secondary transaction in the W12 window)
Alto Neuroscience raised $120 million in a major equity financing for its precision psychiatry platform
Roche unveiled the pharmaceutical industry's largest GPU deployment
Astellas unwound a $1.6 billion biobucks collaboration with CytomX
Bicycle Therapeutics announced a strategic restructuring that shelved its lead program and cut 30% of staff
BioVersys secured IND clearance for a pivotal Phase 3 in drug-resistant pneumonia
Fulgent Genetics closed a $56.9 million diagnostics acquisition,
Zevra Therapeutics sold its entire SDX portfolio to Commave Therapeutics for $50 million in a deal that simultaneously settled Delaware Chancery Court litigation and terminated a 2019 license agreement,
Elaris FlexCo secured an exclusive global license from Valneva for C. difficile vaccine technology
Congruence Therapeutics closed a $39.5 million round and dosed the first patient with CGX-926—a first-in-class oral MC4R corrector for genetic obesity entering the clinic in the same week that Rhythm's MC4R agonist setmelanotide failed Phase 3.
Rhythm simultaneously received FDA approval for IMCIVREE in acquired hypothalamic obesity—making it the first and only therapy approved for that indication and partially offsetting the EMANATE setback.
Endevica Bio spun out Kalohexis to advance a melanocortin system pipeline spanning obesity (710GO) and cancer cachexia (mifomelatide), and Azitra priced a $10.5 million PIPE to fund its live biotherapeutic dermatology programs.
Sobi presented detailed Phase 2a data at ISICEM showing that targeted anti-IFNγ therapy reduced 28-day mortality in a biomarker-selected sepsis population.
Aspen Neuroscience presented landmark 12-month data at AD/PD 2026 showing that all eight Parkinson's patients treated with autologous iPSC-derived neurons showed symptom improvement with confirmed cell engraftment—without immunosuppression.
Combined with a wave of clinical data from AD/PD 2026, EAU 2026, and the Stifel CNS Forum, and over $9 billion in new financing, M&A, and deal activity across PIPEs, convertible notes, venture rounds, debt packages, acquisitions, and asset sales, the W12 window carried more strategic weight than the absence of early-week marquee M&A might suggest.
For dealmakers and investors tracking the pulse of the market, the message from W12 is clear---the data-to-deal pipeline is shortening, platform-level technology collaborations are becoming as strategically significant as traditional licensing agreements, and the week's Friday M&A surge (Novartis/Synnovation, Collegium/Corium) demonstrates that conference-driven data catalysts can translate into billion-dollar transactions within days.
Regulatory Milestones
Aldeyra Therapeutics: Reproxalap Receives Third Complete Response Letter
On March 17, 2026, Aldeyra Therapeutics (NASDAQ: ALDX) disclosed that the FDA issued a third Complete Response Letter for reproxalap, a first-in-class reactive aldehyde species (RASP) modulator submitted as a topical ophthalmic solution for the treatment of dry eye disease. The CRL cited a "lack of substantial evidence" of efficacy, stating that the "totality of evidence from the completed clinical trials does not support the effectiveness of the product." Consistent with the two prior CRLs---the first in November 2023, the second in April 2025---the FDA identified no safety or manufacturing concerns. The decision came one day after the March 16 PDUFA target action date, making reproxalap one of the most prolonged regulatory sagas in ophthalmology.
Mechanism and Competitive Context
Reproxalap represents a genuinely novel mechanism in a therapeutic category dominated by anti-inflammatory (cyclosporine, lifitegrast) and secretagogue (varenicline) approaches. RASP---a class of toxic reactive aldehyde species including malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE)---are elevated on the ocular surface in dry eye disease and directly damage corneal and conjunctival epithelial cells, propagating inflammatory cascades. Reproxalap covalently traps these aldehyde species, breaking the inflammation cycle at an upstream node distinct from downstream immunosuppression.
Regulatory History and Path Forward
The FDA had extended the original PDUFA date from January 2026 to March 16 after requesting an additional Clinical Study Report---a Class II resubmission that reset the three-month review clock. The FDA had shared a draft label with Aldeyra in December 2025 and flagged no major deficiencies by the February 16 deadline for such communications. The NDA resubmission in July 2025 was accepted for review with a standard timeline, suggesting substantive progress toward resolution of prior agency concerns—making the third CRL outcome particularly unexpected.
The CRL noted that label drafts were provided by the FDA in December 2025 and again in March 2026, but Aldeyra does not believe label negotiations were completed. Critically, the FDA recommended exploring reasons for failure in certain trials and identifying populations or conditions in which reproxalap may be effective, but did not recommend conducting additional trials or request additional confirmatory evidence. Aldeyra intends to request a Type A meeting (target within 30 days of receipt), suggesting the company believes the existing data package can be repackaged rather than requiring new clinical studies.
AbbVie Option Agreement: Licensing and Royalty Terms
The exclusive option agreement, originally signed in October 2023 and subsequently expanded, grants AbbVie the option to acquire a co-exclusive license for reproxalap's development, manufacture, and commercialization in the U.S., and an exclusive license for all markets outside the U.S. The deal economics are structured as follows:
| Term | Detail |
|---|---|
| Option fee | $1 million (non-refundable); expanded to $6 million in cumulative option fees |
| Upfront on exercise | $100 million (less previously paid option fees) |
| Regulatory and commercial milestones | Up to $300 million (inclusive of the $100 million FDA approval milestone) |
| U.S. profit/loss split | 60% AbbVie / 40% Aldeyra |
| Ex-U.S. royalties | Tiered royalties on net sales of reproxalap |
| Pre-commercial cost sharing | 60% AbbVie / 40% Aldeyra (if option is exercised) |
| Additional rights | Right of first negotiation for Aldeyra compounds in ocular surface ophthalmology; right to review data on Aldeyra compounds in ophthalmology and immunology before third-party disclosure |
| Option exercise window | 10 business days from FDA approval |
The U.S. profit-sharing structure (rather than a royalty) is notable—it aligns both parties' commercial incentives and gives Aldeyra meaningful economics on U.S. sales, while the tiered ex-U.S. royalty structure reflects AbbVie's sole commercial responsibility outside the United States. The dry eye disease market is projected to exceed $7 billion by 2028, and reproxalap's differentiated mechanism would position it as a potential first-line or combination therapy if approved.
Implications for the AbbVie Option and the Deal Landscape
The third CRL means the $100 million approval milestone is not triggered, and the 10-business-day option exercise window does not open. The option agreement remains in effect, but the path to exercise now requires a successful fourth NDA submission—extending the timeline and increasing the discount rate on any future milestone and profit-sharing economics. For royalty investors and deal structurers, the Aldeyra saga underscores the risk embedded in milestone-contingent option agreements—and the importance of discounting binary regulatory outcomes appropriately, even when signals appear favorable.
BioVersys: FDA IND Clearance for BV100 Phase 3 Pivotal Trial
On March 16, 2026, BioVersys AG announced that the U.S. FDA had cleared its Investigational New Drug (IND) application for BV100 (intravenous rifabutin), enabling enrollment of U.S. patients in the Phase 3 RIV-TARGET pivotal trial for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
Mechanism and Unmet Need
CRAB infections represent one of the most critical unmet needs in antimicrobial resistance. The WHO classifies CRAB as a Priority 1 (Critical) pathogen, and mortality rates for CRAB HABP/VABP routinely exceed 40-60% even with best available therapy. BV100 reformulates rifabutin---a lipophilic ansamycin antibiotic historically used for mycobacterial infections---as an intravenous formulation that achieves bactericidal concentrations against CRAB isolates.
Phase 2 Results and Trial Design
The Phase 2 data were striking: BV100 demonstrated a 50% relative reduction in 28-day all-cause mortality (25% versus 60% on best available therapy) in CRAB HABP/VABP patients. The Phase 3 RIV-TARGET trial will enroll approximately 300 patients globally, with topline results expected by end of 2027. The trial uses an adaptive design with a pre-planned interim analysis.
BioVersys, headquartered in Basel, previously raised CHF 70 million in a 2024 Series D. The IND clearance expands the trial footprint to U.S. sites alongside existing European enrollment, accelerating the path to a potential Breakthrough Therapy-eligible regulatory submission.
Roche Diagnostics: CE Mark for Elecsys ApoE4 Immunoassay
On March 16, 2026, Roche announced CE Mark approval for the Elecsys ApoE4 blood test, the first in-vitro diagnostic (IVD) immunoassay capable of identifying carriers of the ApoE ε4 genetic variant from a standard blood sample. In a 607-participant multicenter clinical validation study, the test demonstrated 100% concordance with genetic sequencing for ApoE4 carrier identification and eliminated the need for confirmatory genetic testing in non-carriers.
The ApoE ε4 allele is the strongest common genetic risk factor for late-onset Alzheimer's disease and is present in up to 60% of diagnosed patients. As disease-modifying anti-amyloid therapies (lecanemab, donanemab) enter clinical practice, ApoE4 genotyping has become a critical component of treatment decision-making due to the elevated risk of amyloid-related imaging abnormalities (ARIA) in ApoE4 carriers, particularly homozygotes. The Elecsys ApoE4 test complements Roche's recently CE-marked Elecsys pTau181 blood test, building a blood-based Alzheimer's diagnostic panel that could meaningfully reduce reliance on amyloid PET imaging and CSF biomarker testing.
Johnson & Johnson / Protagonist Therapeutics: ICOTYDE (Icotrokinra) FDA Approval
On March 18, 2026, Johnson & Johnson received FDA approval for ICOTYDE (icotrokinra), the first-in-class oral IL-23 receptor antagonist for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.
Mechanism and Clinical Data
ICOTYDE binds to the IL-23 receptor with single-digit picomolar affinity and delivers potent, selective inhibition of IL-23 signaling---achieving the efficacy of injectable IL-23 pathway blockade in a once-daily oral formulation. The approval was supported by four Phase 3 studies (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, ICONIC-ADVANCE 2) enrolling approximately 2,500 patients, which met all primary endpoints. In the pivotal ICONIC-LEAD trial, approximately 70% of patients achieved IGA 0/1 (clear or almost clear skin) at Week 16 and approximately 55% achieved PASI 90, with demonstrated superiority over BMS's Sotyktu (deucravacitinib) in a head-to-head comparison. The FDA granted a clean label without mandatory tuberculosis testing---a meaningful practical advantage over JAK inhibitors.
Licensing and Royalty Terms
ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists under a license and collaboration agreement established in 2017, with Protagonist having primary responsibility for development through Phase 1 and J&J assuming responsibility for further development and commercialization.
| Term | Detail |
|---|---|
| Original agreement | 2017 License and Collaboration Agreement (Protagonist / Janssen Biotech) |
| Upfront payment | $50 million (received 2017) |
| Total milestones earned to date | $337.5 million (through December 31, 2024) |
| FDA approval milestone | $50 million (triggered March 18, 2026) |
| Remaining milestone potential | Up to $580 million in future regulatory and sales milestones |
| Royalties | Tiered 6-10% on global net sales (weighted-average ~7.25% at $4B annual sales; top tier of 10% on sales above $4 billion) |
| Peak sales estimates | $5-10 billion (Truist Securities) |
| Additional indications in development | Psoriatic arthritis, ulcerative colitis (Phase 2b ANTHEM), Crohn's disease |
| Protagonist cash position | $646 million (Q4 2025), with runway into end of 2028 before milestone payments |
The ICOTYDE approval is the most consequential licensing event of W12 for royalty investors. The 6-10% tiered royalty structure on a projected $5-10 billion peak-sales franchise creates a royalty stream that, at the midpoint of peak sales estimates, would generate $500-725 million in cumulative royalty income annually at maturity. For context, the weighted-average royalty rate of approximately 7.25% at $4 billion in sales compares favorably to the CytomX/Astellas terminated deal (high-single-digit to mid-teens) and the Almirall/Lilly EBGLYSS European royalties (rates not publicly disclosed). Protagonist's $646 million cash position and the additional $580 million in remaining milestones give the company substantial financial flexibility---and make the Protagonist royalty stream a potential acquisition target for royalty aggregators.
Protagonist also has a separate collaboration with Takeda for rusfertide (a hepcidin mimetic for polycythemia vera), under which Protagonist is eligible for tiered royalties of 10-17% on ex-U.S. net sales and a 50/50 U.S. profit-sharing arrangement---with an option to opt out for up to $400 million in payments and 14-29% tiered worldwide royalties instead. Protagonist's January 2026 investor presentation and 10-K filing confirm that the company currently expects to exercise its full opt-out right in Q2 2026, which would trigger a $200 million opt-out payment plus $200 million upon FDA approval ($400 million total), enhanced milestones of up to $975 million (versus $330 million if opted in), and worldwide tiered royalties of 14% to 29% on net sales---with the 29% top tier applying at annual net sales of $1.5 billion or above and a weighted-average royalty rate of approximately 21% at $1.5 billion. One percent of all royalties is payable to an undisclosed third party. The rusfertide NDA has been accepted by the FDA with Priority Review and a PDUFA date in Q3 2026.
Novo Nordisk: Wegovy HD (Semaglutide 7.2 mg) FDA Approval
On March 19, 2026, the FDA approved Wegovy HD (semaglutide injection 7.2 mg), a higher-dose formulation of Novo Nordisk's blockbuster GLP-1 receptor agonist, for long-term weight reduction in adults with obesity or overweight with at least one weight-related condition who have tolerated the 2.4 mg dose for at least four weeks. Wegovy HD is the first GLP-1 treatment approved under the Commissioner's National Priority Voucher (CNPV) pilot program, completing FDA review in just 54 days---underscoring the new regulatory pathway's potential to accelerate approvals for products addressing critical national health priorities.
Key Efficacy Results
| Trial | Population | Weight Loss (Efficacy Estimand) | Key Detail |
|---|---|---|---|
| STEP UP (72 weeks, N~1,400) | Adults with obesity, no diabetes | 20.7% mean weight loss (7.2 mg) | 31.2% of patients achieved ≥25% weight loss |
| STEP UP (72 weeks) | Adults with obesity, no diabetes | ~18% (treatment regimen estimand) | Superior to 2.4 mg (~15% in pivotal trials) |
| STEP UP T2D (72 weeks, N~500) | Adults with obesity + type 2 diabetes | 14.1% mean weight loss | Safety consistent with known semaglutide profile |
Safety and Clinical Considerations
The most common adverse reactions were nausea, vomiting, constipation, abdominal pain, fatigue, headache, dizziness, hair loss, and flatulence. Notably, dysesthesia (altered skin sensations including burning, stabbing, or electrical shock-like feelings) was reported in 22% of Wegovy HD patients versus 6% at 2.4 mg and less than 1% with placebo---a dose-dependent safety signal that the FDA noted it is further investigating. These events were generally mild and tended to resolve spontaneously or with dose reduction.
Commercial and Market Implications
Wegovy HD will be available in April 2026 via a single-dose pen through 70,000+ U.S. pharmacies. The 7.2 mg dose is already approved in the EU and UK, with regulatory decisions on the single-dose pen format in those markets expected in H2 2026. The approval adds a third distinct injectable option to Novo Nordisk's semaglutide obesity portfolio, alongside the existing 2.4 mg injection and the 25 mg once-daily oral pill approved in December 2025. Wegovy HD is wholly owned by Novo Nordisk with no external licensing or royalty partners.
For the GLP-1/obesity competitive landscape, the Wegovy HD approval in the same week as Structure Therapeutics' aleniglipron Phase 2 data (16.3% weight loss with an oral small molecule), ProLynx's $70 million Series A for longer-acting incretin therapies, Lilly's retatrutide Phase 3 diabetes success (16.8% weight loss with a triple agonist), and the Samsung Bioepis/G2GBIO long-acting semaglutide collaboration underscores the intensifying arms race across formulations, mechanisms, and dosing intervals in the obesity therapeutic space.
GSK: Lynavoy (Linerixibat) FDA Approval for Cholestatic Pruritus in PBC
On March 19, 2026, the FDA approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adults with primary biliary cholangitis (PBC), ahead of its March 24 PDUFA date. Linerixibat is an ileal bile acid transporter (IBAT) inhibitor that reduces the enterohepatic circulation of bile acids, addressing the debilitating itch that affects up to 70% of PBC patients. The approval was based on positive Phase 3 GLISTEN data. GSK retains full commercial rights; no external licensing or royalty arrangements have been disclosed.
AstraZeneca: Imfinzi (Durvalumab) EU Approval for Early Gastric Cancer
On March 16, 2026, the European Commission granted marketing authorization for Imfinzi (durvalumab) plus FLOT chemotherapy for the perioperative treatment of resectable Stages II, III, and IVA gastric and gastroesophageal junction (GEJ) adenocarcinoma—the first and only perioperative immunotherapy approved in the EU for this indication. The approval was based on the Phase 3 MATTERHORN trial (948 patients, 176 centers, 20 countries), which demonstrated a 29% reduction in the risk of disease progression, recurrence, or death (EFS HR 0.71, p<0.001) and a 22% reduction in the risk of death (OS HR 0.78, p=0.021), with approximately 69% of patients alive at three years. The MATTERHORN overall survival data were simultaneously published in the New England Journal of Medicine. This is AstraZeneca's third perioperative EU approval for an Imfinzi-based regimen. Imfinzi is wholly owned by AstraZeneca with no external royalty partners for this indication.
Clinical Data Readouts
Eli Lilly EBGLYSS Phase 3 ADorable-1 in Pediatric Atopic Dermatitis
On March 16, 2026, Eli Lilly and Company announced positive topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients aged six months to 18 years with moderate-to-severe atopic dermatitis. EBGLYSS met both co-primary endpoints at Week 16, establishing itself as the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes across the full pediatric age spectrum down to infancy.
Mechanism and Competitive Context
EBGLYSS is a monoclonal antibody that selectively targets interleukin-13 (IL-13), a key type 2 cytokine that drives the pathological hallmarks of atopic dermatitis: epidermal barrier disruption, skin inflammation, pruritis, and susceptibility to infection. Unlike dupilumab (Dupixent, Sanofi/Regeneron), which inhibits both IL-4 and IL-13 signaling through blockade of the shared IL-4Rα receptor subunit, lebrikizumab binds directly to IL-13 at a specific epitope that prevents formation of the IL-13Rα1/IL-4Rα heterodimer signaling complex—achieving selective IL-13 neutralization while leaving IL-4 signaling through the type I receptor intact.
This mechanistic distinction is clinically relevant: IL-4 plays important roles in B-cell class switching, Th2 differentiation, and certain protective immune functions, and the selective IL-13 approach may offer a differentiated tolerability profile, particularly in young children whose immune systems are still maturing.
Key Efficacy Results
| Endpoint | EBGLYSS | Placebo |
|---|---|---|
| EASI-75 (meaningful skin improvement) at Week 16 | 63% | 22% |
| IGA 0/1 (clear or almost clear skin) at Week 16 | 44% | 15% |
| EASI-90 (near-complete skin clearance) at Week 16 | 39% | Not disclosed |
| Pruritus NRS ≥4-point improvement (significant itch relief) | 35% | Not disclosed |
The safety and tolerability profile of EBGLYSS was consistent with previously reported adult and adolescent studies, with no new safety signals identified. Notably, no injection site pain was reported across the pediatric population---a meaningful practical advantage for a therapy that will be administered to children as young as six months.
Strategic and Market Implications
Atopic dermatitis affects approximately 9.6 million children in the United States, with roughly one-third experiencing moderate-to-severe disease. The global AD biologics market, currently dominated by Dupixent (which generated approximately $14 billion in 2025 sales across all indications), is expanding rapidly as new entrants seek to capture share across increasingly segmented age populations.
Lilly plans to submit the ADorable-1 data to US and global regulators for a potential label update expanding the approved age range below 12 years. Lilly holds exclusive rights for development and commercialization of EBGLYSS in the United States and the rest of the world outside Europe. Lilly's partner Almirall S.A. has licensed the rights to develop and commercialize EBGLYSS for dermatology indications, including atopic dermatitis, in Europe---a regional licensing structure that reflects the asset's origins in Dermira (acquired by Almirall's predecessor licensee) and subsequent global rights repartitioning.
European License Structure: Almirall/Dermira Agreement
The European rights trace back to a 2019 option and license agreement between Dermira and Almirall, subsequently inherited by Lilly following its acquisition of Dermira. The original deal economics included:
| Term | Detail |
|---|---|
| Option fee | $30 million |
| Option exercise fee | $50 million |
| Phase 3 initiation milestones | Up to $30 million |
| Regulatory milestones | Up to $40 million |
| First commercial sale (EU) | $45 million |
| Sales-based milestones (Europe) | Up to $1.25 billion, tied to annual net sales thresholds ranging from $86 million to $3 billion (each milestone representing approximately 7-15% of the applicable threshold) |
| Royalties | Tiered royalties on European net sales ranging from the low double-digits to the low twenties (~10-12% to ~20-23%) based on annual net sales thresholds; royalty term per country until the later of 10 years post-first commercial sale, last valid patent expiry, or regulatory exclusivity expiry |
| Upstream royalties | Roche receives tiered royalties from high single-digits to high teens from Lilly (as Dermira's successor) under the 2017 lebrikizumab license |
The deal structure is notable for its heavy back-end weighting toward sales-based milestones, reflecting the commercial optionality in a market where Dupixent (Sanofi/Regeneron) had already established a dominant position. Almirall's European-only scope and Lilly's retention of U.S. and rest-of-world rights creates a geographically segmented royalty and milestone structure relevant for investors tracking the asset's global economics.
Key competitors in the pediatric AD space include Dupixent (approved down to 6 months), AbbVie's Rinvoq (upadacitinib, a JAK inhibitor approved for adolescents 12+), and Pfizer's Cibinqo (abrocitinib, JAK1 inhibitor, adults only). Tralokinumab (Adbry/Adtralza, LEO Pharma), another IL-13 inhibitor, is approved for adults and adolescents 12+ but has not yet reported pediatric data in younger children.
Pfizer: Atirmociclib Phase 2 FOURLIGHT-1 Positive Results in Metastatic Breast Cancer
On March 17, 2026, Pfizer announced positive topline results from the Phase 2 FOURLIGHT-1 trial evaluating atirmociclib, a potential first-in-class selective CDK4 inhibitor, in second-line HR+/HER2- metastatic breast cancer patients who had progressed on prior CDK4/6 inhibitor therapy.
Key Results
| Endpoint | Atirmociclib + Fulvestrant | Comparator |
|---|---|---|
| Primary: Progression-free survival (HR) | 0.60 (p=0.0007) | --- |
| Risk reduction | 40% reduction in disease progression or death | --- |
| Population | >90% initiated within 3 months of last CDK4/6i | --- |
The results are clinically significant because the trial enrolled patients with recent CDK4/6 inhibitor exposure—a population where resistance mechanisms are active and response rates to existing second-line therapies are modest. Atirmociclib's selectivity for CDK4 over CDK6 is the mechanistic differentiator: by sparing CDK6-dependent hematopoietic stem cell cycling, the drug may offer improved neutropenia profiles relative to current CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), which are dual CDK4/6 inhibitors.
Pfizer is advancing a separate Phase 3 trial in first-line HR+/HER2- metastatic breast cancer. Atirmociclib is positioned as a successor to Pfizer's own Ibrance (palbociclib), which generated $1.04 billion in 2025 revenue but faces a 2027 patent cliff. No external licensing or royalty arrangements have been disclosed for atirmociclib.
Structure Therapeutics: Aleniglipron Phase 2 ACCESS II Obesity Data
On March 16, 2026, Structure Therapeutics (NASDAQ: GPCR) reported positive topline data from the Phase 2 ACCESS II trial of aleniglipron, an oral, once-daily small molecule GLP-1 receptor agonist, in patients with obesity.
Key Efficacy Results
| Endpoint | 180 mg (highest dose) | Placebo |
|---|---|---|
| Placebo-adjusted body weight loss at 44 weeks | 16.3% (~39 lbs, p<0.0001) | --- |
| AE-related discontinuation | 2.0-3.4% | --- |
| Weight-loss plateau | No evidence of plateau at 44 weeks | --- |
| Safety signals | No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation | --- |
The results across more than 625 participants position aleniglipron as a competitive oral alternative to injectable GLP-1 agonists (semaglutide, tirzepatide) in the rapidly expanding obesity market. Structure plans an end-of-Phase 2 FDA meeting in Q2 2026 and Phase 3 initiation in H2 2026. Shares rose approximately 8.7% on the announcement. No external licensing or royalty arrangements have been disclosed; Structure retains full global rights to aleniglipron.
Eli Lilly: Retatrutide Phase 3 TRANSCEND-T2D-1 Positive Results in Type 2 Diabetes
On March 19, 2026, Eli Lilly announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide, an investigational first-in-class GIP/GLP-1/glucagon triple hormone receptor agonist, in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The trial met its primary endpoint and all key secondary endpoints.
Key Efficacy Results
| Endpoint | Retatrutide 4 mg | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|---|
| A1C reduction (primary) | -1.7% | -1.9% | -2.0% | -0.8% |
| Body weight loss | -12% (~26 lbs) | -14% (~30 lbs) | -16.8% (36.6 lbs) | -2.5% |
| Weight loss plateau | No plateau observed at 40 weeks | --- | --- | --- |
The trial enrolled more than 2,050 adults with a mean diabetes duration of 2.5 years across three dose groups (4 mg, 9 mg, 12 mg) and placebo. Clinically meaningful improvements in cardiovascular risk factors---non-HDL cholesterol, triglycerides, and systolic blood pressure---were also observed. The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), occurring primarily during dose escalation. Dysesthesia occurred in 2.3-4.5% of retatrutide-treated patients (versus 0.0% with placebo), generally mild and resolving during treatment. Discontinuation rates due to adverse events were 2.2-5.1% across doses.
Strategic Context
The TRANSCEND-T2D-1 results position retatrutide as potentially more potent than Lilly's own tirzepatide (Mounjaro/Zepbound), which targets only two of the three receptors. The 16.8% weight loss at the 12 mg dose—in a 40-week diabetes trial not designed to maximize weight loss—signals that the dedicated obesity program (TRIUMPH) results, expected mid-2026, could deliver even more substantial weight reduction. With seven additional Phase 3 readouts expected in 2026 across obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, chronic low back pain, cardiovascular/renal outcomes, and metabolic liver disease, retatrutide is poised to be the most comprehensively studied next-generation metabolic drug in history. No external licensing or royalty arrangements have been disclosed; Lilly retains full global rights.
Pfizer: TALAPRO-3 Phase 3 Positive Results in Metastatic Castration-Sensitive Prostate Cancer
On March 19, 2026, Pfizer announced positive topline results from the Phase 3 TALAPRO-3 trial evaluating TALZENNA (talazoparib) plus XTANDI (enzalutamide) versus placebo plus enzalutamide in patients with HRR gene-mutated metastatic castration-sensitive prostate cancer (mCSPC)---the first PARP inhibitor combination to demonstrate Phase 3 efficacy in this earlier disease setting.
Key Results
| Endpoint | Result |
|---|---|
| Primary: Radiographic progression-free survival (rPFS) | Statistically significant and clinically meaningful improvement |
| Hazard ratio | Markedly exceeded pre-specified target of 0.63 |
| Progression-free patients | Majority remained progression-free at time of analysis |
| BRCA vs. non-BRCA | Consistent efficacy across both subgroups |
| Interim overall survival | Strong trend toward improvement (data not yet mature) |
| Additional secondary endpoints | ORR, DOR, and time to PSA progression all favored talazoparib arm |
The trial enrolled 599 patients across the U.S., Canada, Europe, South America, and Asia-Pacific, using a 12-gene HRR panel (HRR12) for patient selection. The safety profile was consistent with known profiles of each individual agent, with no new safety signals. Talazoparib plus enzalutamide is already approved in over 60 countries for HRR-mutated metastatic castration-resistant prostate cancer (mCRPC); the TALAPRO-3 results support potential label expansion into the earlier mCSPC setting, where approximately 25% of metastatic prostate cancer patients carry HRR gene mutations.
Pfizer plans to discuss the results with global health authorities for potential regulatory submissions. The TALAPRO-3 data, combined with the Pfizer atirmociclib Phase 2 win in breast cancer reported earlier in W12 and the PF-08046031 discontinuation, demonstrate Pfizer's ongoing portfolio rationalization post-Seagen---investing in high-conviction programs while terminating underperformers.
Xtandi (Enzalutamide) Licensing and Royalty Structure
The TALAPRO-3 combination partner Xtandi carries a layered licensing and royalty structure relevant to the deal's commercial economics. Xtandi was discovered at Medivation, Inc. (acquired by Pfizer for $14 billion in September 2016) and is co-developed and co-promoted with Astellas Pharma under a 2009 collaboration agreement that included a $110 million upfront payment from Astellas, up to $335 million in development and regulatory milestones, up to $320 million in commercial milestones, a 50/50 U.S. pre-tax profit split, and double-digit percentage royalties from Astellas on ex-U.S. net sales (Astellas has sole ex-U.S. commercialization responsibility). Clinical trial costs are split equally for U.S.-only trials and one-third/two-thirds (Medivation/Astellas) for global trials.
Critically for royalty investors, Xtandi also carries an upstream 4% royalty on global net sales payable under an August 2005 exclusive license from the University of California, Los Angeles (UCLA), where the drug was co-invented by Professor Charles Sawyers and Professor Michael Jung. UCLA also receives 10% of sublicensing income. In March 2016, UCLA sold its royalty interest to Royalty Pharma for $1.14 billion (with UCLA receiving approximately $520 million), making the Xtandi royalty stream one of the most valuable academic royalty monetizations in pharmaceutical history. Royalty Pharma now receives the ongoing 4% royalty on all global Xtandi sales. Given that Xtandi generated approximately $4.5 billion in global sales in 2024, the UCLA/Royalty Pharma royalty stream alone is worth approximately $180 million annually—a figure that underscores the long-duration value of composition-of-matter royalties on blockbuster oncology franchises. The TALAPRO-3 label expansion into mCSPC, if approved, would further increase the revenue base on which this royalty is calculated.
Roche/Genentech: Emugrobart Discontinued in SMA and FSHD
On March 19, 2026, Roche and its subsidiary Genentech announced the discontinuation of emugrobart (GYM329), an anti-myostatin antibody developed by Chugai Pharmaceutical, in both spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD) after the drug failed to demonstrate consistent improvements in muscle growth and motor function.
In SMA, emugrobart was tested in the Phase 2/3 MANATEE trial (NCT05115110; 259 patients enrolled) in combination with Roche's marketed SMA therapy Evrysdi (risdiplam). In FSHD, the Phase 2 MANOEUVRE trial (NCT05548556) evaluated emugrobart as a standalone therapy. Both trials showed that emugrobart did not consistently deliver the improvements hoped for in muscle growth---a finding that was not related to safety concerns. Roche plans to share detailed data from both trials at upcoming medical congresses.
The competitive beneficiary is Scholar Rock (NASDAQ: SCLX), whose rival anti-myostatin candidate apitegromab is now the sole remaining muscle-enhancing therapy in SMA development. Scholar Rock's stock rose 16% on the news. Truist Securities described emugrobart's exit as setting "the stage for apitegromab domination." Scholar Rock plans to initiate a Phase 2 study of apitegromab in FSHD by mid-2026.
Roche/Chugai Licensing Economics
Emugrobart (GYM329/RG6237) is a humanized anti-latent myostatin "sweeping antibody" invented by Chugai Pharmaceutical Co., Ltd. (TYO: 4519) using its proprietary recycling antibody technology. Roche owns approximately 59.9% of Chugai, and the two companies operate under a 2002 Basic Alliance Agreement that grants Roche first refusal rights on Chugai-originated products for development and commercialization outside Japan. Under this framework, Chugai typically receives upfront fees, milestone payments, and royalties when it out-licenses products to Roche for global development---though specific financial terms for individual molecules are not publicly disclosed due to the parent-subsidiary relationship. The precedent set by satralizumab (Enspryng), another Chugai-originated antibody commercialized globally by Roche under the same alliance, followed this exact structure. Chugai's 2024 royalty and profit-sharing income from Roche (driven primarily by the blockbuster Hemlibra franchise) was forecast at approximately JPY 217.2 billion ($1.4 billion), reflecting the material scale of the Roche-Chugai economic relationship. The emugrobart discontinuation in SMA and FSHD eliminates a potential future royalty stream for Chugai from these indications, though Roche continues to develop emugrobart in obesity and type 2 diabetes.
Notably, Roche continues to develop emugrobart for obesity (Phase 2 GYMINDA trial in combination with Eli Lilly's Zepbound) and type 2 diabetes (Phase 1)---though the failure to improve muscle growth in SMA and FSHD raises questions about whether the drug can preserve lean mass in obesity patients losing weight on GLP-1 agonists, a key hypothesized benefit.
Roche/Genentech: Flizasertib (GDC-8264) Phase 2 Terminated in Acute Kidney Injury
In the same week, Genentech terminated its Phase 2 trial of flizasertib (GDC-8264), a selective RIPK1 (receptor-interacting serine/threonine-protein kinase 1) inhibitor, for the prevention of cardiac surgery-associated acute kidney injury after an interim analysis of 67 patients indicated the study was unlikely to demonstrate significant clinical benefit. The asset was removed from Genentech's pipeline. Genentech retains a separate Phase 1b trial of flizasertib in acute graft-versus-host disease.
The termination extends a broader pattern of RIPK1 inhibitor class failures—GSK, Sanofi/Denali, and Lilly have all retreated from RIPK1 programs—and raises fundamental questions about whether RIPK1 inhibition can translate preclinical promise into clinical efficacy in acute inflammatory settings.
Bayer: KERENDIA (Finerenone) FIND-CKD Phase 3 Positive in Non-Diabetic CKD
On March 16, 2026, Bayer announced that KERENDIA (finerenone) met the primary endpoint in the Phase 3 FIND-CKD trial, demonstrating statistically significant improvement in eGFR slope in patients with non-diabetic chronic kidney disease—the largest Phase 3 study in this population to date. This is finerenone's fifth consecutive positive pivotal Phase 3 trial (after FIDELIO-DKD, FIGARO-DKD, FINE-ONE, and FINEARTS-HF).
A label extension to non-diabetic CKD could approximately double KERENDIA's addressable market, given that roughly half of the estimated 850 million people globally with CKD do not have diabetes. KERENDIA generated approximately EUR 829 million in 2025 sales (up 79% year-over-year), and Bayer is targeting peak sales exceeding $3 billion. The FIND-CKD results are expected to support a supplemental NDA filing with the FDA. KERENDIA is fully owned by Bayer with no external licensing or royalty partners, making this a purely internal franchise expansion. Finerenone was discovered and developed entirely in-house by Bayer (internal designation BAY 94-8862); foundational patents (US8436180B2, filed 2008) list exclusively Bayer employees as inventors, and no evidence of any upstream in-licensing, academic origin, or third-party royalty obligations exists in Bayer's annual reports, patent records, or regulatory filings—making KERENDIA one of the few potential multi-billion-dollar blockbusters with a confirmed zero upstream royalty burden. The CKD market context is directly relevant to the R1 Therapeutics/Alebund AP306 deal discussed below—both assets target CKD patients on dialysis, and finerenone's market expansion increases the competitive and commercial context for new entrants.
Rhythm Pharmaceuticals: Imcivree Phase 3 EMANATE Failure
On March 16, 2026, Rhythm Pharmaceuticals (NASDAQ: RYTM) announced that all four substudies of the Phase 3 EMANATE trial evaluating Imcivree (setmelanotide) in rare MC4R pathway diseases failed to meet their primary endpoints (52-week BMI change versus placebo):
| Substudy | Population | BMI Reduction | p-value |
|---|---|---|---|
| POMC/PCSK1 heterozygotes | MC4R pathway | -4.3% | 0.15 |
| LEPR heterozygotes | MC4R pathway | -3.6% | 0.94 |
| SRC1 | MC4R pathway | -4.0% | 0.12 |
| SH2B1 | MC4R pathway | -1.7% | 0.43 |
Post-hoc analyses showed statistical significance in the POMC/PCSK1 and SRC1 cohorts, but the primary analysis is negative. Rhythm was simultaneously awaiting a critical PDUFA decision on March 20 for Imcivree in acquired hypothalamic obesity, with the FDA having extended the review period. Shares fell approximately 6%. The EMANATE failure limits the commercial expansion potential for Imcivree beyond its approved rare obesity indications and narrows the addressable patient population for Rhythm's MC4R agonist platform.
BioMarin: Voxzogo Phase 2 Trial Suspensions (Safety Signal)
Rhythm Pharmaceuticals: IMCIVREE FDA Approval for Acquired Hypothalamic Obesity
On March 19, 2026, Rhythm Pharmaceuticals (NASDAQ: RYTM) announced that the FDA approved an expanded indication for IMCIVREE (setmelanotide) for the treatment of acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older---making IMCIVREE the first and only FDA-approved therapy for this rare condition. Acquired HO is characterized by accelerated and sustained weight gain caused by injury to the hypothalamus or hypothalamic dysfunction, most commonly following treatment of craniopharyngioma or other hypothalamic-pituitary tumors.
Clinical Data and Regulatory History
The approval was based on the Phase 3 TRANSCEND trial (N=142), which demonstrated a -18.8% placebo-adjusted BMI reduction at 52 weeks (setmelanotide -16.4% vs. placebo +2.4%; p<0.0001). The dataset included 12 patients from a Japanese cohort and 10 supplemental patients enrolled beyond the original 120-patient pivotal cohort, all confirming consistent efficacy. The most common adverse events (incidence >20%) were skin hyperpigmentation, nausea, vomiting, and headache. In patients with secondary adrenal insufficiency—a common comorbidity in the acquired HO population—serious adverse reactions related to acute adrenal insufficiency were reported in 5% of IMCIVREE-treated patients.
The FDA had originally assigned a PDUFA date of December 20, 2025, subsequently extended to March 20, 2026 after the agency requested additional sensitivity analyses of clinical efficacy data (a Class II resubmission). The approval came one day ahead of the revised PDUFA date.
Commercial and Strategic Context
Rhythm estimates approximately 10,000 people in the U.S. live with acquired hypothalamic obesity. IMCIVREE generated $194.8 million in FY2025 global product revenue ($57.3 million in Q4 2025 alone, +12% sequentially) across its approved rare genetic obesity indications (BBS, POMC/PCSK1 deficiency, LEPR deficiency). The acquired HO label expansion significantly broadens the addressable patient population and provides a commercial growth vector independent of the EMANATE setback in rare MC4R pathway diseases earlier in the week.
The W12 juxtaposition is striking: Rhythm's EMANATE Phase 3 failed all four substudies in genetically defined MC4R pathway diseases (March 16), while the IMCIVREE acquired HO approval (March 19) opens a new, larger patient population. For dealmakers tracking the melanocortin space, the approval reinforces IMCIVREE's commercial franchise in obesity indications driven by hypothalamic injury, even as the genetic obesity expansion strategy narrows. Combined with Congruence Therapeutics' first-patient dosing of CGX-926 (a first-in-class MC4R corrector) and Endevica Bio's Kalohexis spin-out (710GO dual MC3R/MC4R agonist) in the same week, the melanocortin therapeutic landscape experienced a pivotal reshuffling—with acquired HO emerging as IMCIVREE's strongest commercial pillar going forward. Rhythm plans to initiate a Phase 3 trial of bivamelagon, its oral MC4R agonist, in acquired HO by year-end 2026 following a constructive end-of-Phase-2 meeting with the FDA.
On March 16, 2026, BioMarin (NASDAQ: BMRN) announced the suspension of dosing and enrollment in Phase 2 trials of Voxzogo (vosoritide) in Turner syndrome, SHOX-deficiency, and ACAN-deficiency after several cases of slipped capital femoral epiphysis (SCFE) were reported in investigator-sponsored trials studying higher-than-approved doses. No SCFE events have occurred in BioMarin's own clinical trials or in over 5,000 achondroplasia patients treated across more than 10,000 patient-years of commercial exposure. Trials in Noonan syndrome and idiopathic short stature continue unaffected.
Voxzogo generated $927 million in 2025 sales in its approved achondroplasia indication. The trial suspensions do not affect the approved indication but limit the near-term expansion potential of the Voxzogo franchise into adjacent short-stature conditions. BioMarin filed an 8-K with the SEC disclosing the suspensions. Voxzogo is fully owned by BioMarin with no external royalty or licensing partners.
CytomX Therapeutics: Varseta-M Phase 1 Expansion in Metastatic Colorectal Cancer
On March 16, 2026, CytomX Therapeutics reported encouraging Phase 1 expansion results for varsetatug masetecan (Varseta-M), a Probody antibody-drug conjugate targeting EpCAM, in 93 patients with late-line metastatic colorectal cancer (mCRC).
Key Efficacy and Safety Results
| Endpoint | Result |
|---|---|
| Confirmed ORR at 10 mg/kg (n=53) | 32% |
| Disease control rate | ~90% |
| Estimated median PFS | 7.1 months |
| Grade ≥3 diarrhea (with optimized prophylaxis) | 10% |
These results are notable in a population that has failed multiple prior lines of therapy, where response rates to approved agents (regorafenib, trifluridine/tipiracil) are typically in the single digits. The 32% confirmed ORR at 10 mg/kg and estimated 7.1-month PFS suggest meaningful clinical activity.
Probody Technology and Pipeline Context
EpCAM is broadly expressed on epithelial tumors but also on normal gastrointestinal tissue, which has historically limited the therapeutic window for EpCAM-targeting agents. CytomX's Probody platform addresses this by engineering a protease-activatable masking peptide that shields the antibody's binding site until cleaved by tumor-associated proteases in the tumor microenvironment. This conditional activation is designed to reduce on-target, off-tumor toxicity---critical for an ADC targeting the GI epithelium.
CytomX plans mid-year FDA discussions for a potential registrational study design, with combination trials with bevacizumab already underway. This positive dataset partially offsets the negative news from the Astellas collaboration termination (detailed below).
Lundbeck Pipeline Presentations at AD/PD 2026
On March 16, 2026, H. Lundbeck A/S announced a series of presentations at the 2026 Alzheimer's and Parkinson's Disease (AD/PD) conference in Copenhagen (March 17-21), including new Phase 1b data on Lu AF28996, a novel orally administered dopamine D1/D2 receptor agonist being developed for advanced Parkinson's disease.
Lu AF28996 is designed to provide continuous dopaminergic stimulation and is being investigated for its potential to improve motor fluctuations and levodopa-induced dyskinesia—the debilitating "on-off" cycling that progressively limits quality of life in patients with advanced Parkinson's disease. The Phase 1b proof-of-mechanism trial evaluated safety, tolerability, pharmacokinetics, and exploratory clinical activity in patients with advanced disease. Based on the results, Lundbeck is initiating a Phase 2 study in 2026.
Lundbeck's movement disorders pipeline also includes amlenetug, a human monoclonal antibody targeting all major forms of extracellular α-synuclein, being developed under a joint research and licensing agreement with Genmab A/S for the potential treatment of multiple system atrophy (MSA). Amlenetug has accumulated a strong portfolio of regulatory designations: FDA Fast Track Designation (February 2025), FDA Orphan Drug Designation (April 2024), EMA Orphan Drug Designation (May 2021), SAKIGAKE designation from Japan's MHLW (March 2023), and Japanese Orphan Drug Designation (March 2025). The Phase 2 AMULET trial (n=61) showed a consistent slowing of clinical progression, with a post-hoc analysis of a less impaired subgroup demonstrating a 42% slowing of progression versus placebo. The company announced on March 9 that the last patient had been randomized ahead of schedule in the Phase 3 MASCOT trial, with headline results anticipated in Q3 2027 and expected launch in Q1 2029. The AD/PD presentations will include advances in MSA disease progression understanding and Bayesian progression modeling for clinical trial outcomes. The Lundbeck-Genmab licensing agreement, originally signed in October 2010 as a joint research and licensing agreement for human antibody therapeutics targeting CNS disorders, included an upfront payment of EUR 7.5 million (~$10.4 million), total potential milestones of up to EUR 38 million (inclusive of upfront), and single-digit percentage royalties to Genmab on commercialized products. Lundbeck fully funds all development costs. Genmab retains an option on non-CNS indications, subject to milestones and reciprocal single-digit royalties to Lundbeck. Lundbeck also bears the majority of Genmab's payments to Medarex (now BMS) under the underlying UltiMab technology license.
The conference presentations underscore Lundbeck's broadening commitment to movement disorders beyond its legacy psychiatry and neurology franchises, and its growing pipeline depth following the December 2024 acquisition of Longboard Pharmaceuticals.
AD/PD 2026 Conference Data: Neuroscience Pipeline in Focus
The 20th International Conference on Alzheimer's & Parkinson's Diseases opened in Copenhagen on March 17 with a dense schedule of clinical data presentations from companies across the neuroscience pipeline. Several readouts carry direct strategic implications for dealmakers.
Eisai / BioArctic / Biogen: Lecanemab (Leqembi) Long-Term and Real-World Data
Eisai announced six presentations at AD/PD 2026, headlined by 4-year open-label extension data from the Clarity AD trial---the longest follow-up dataset for any anti-amyloid antibody in early Alzheimer's disease. Additional presentations covered real-world U.S. treatment persistence patterns and efficacy/safety in ApoE ε4 homozygous carriers, the highest-risk population for amyloid-related imaging abnormalities (ARIA). Lecanemab is now approved in 53 countries, with subcutaneous maintenance dosing approved in the U.S. since August 2025 and a supplemental BLA for subcutaneous initiation dosing carrying a PDUFA date of May 24, 2026.
ImmunoBrain: IBC-Ab002 Phase 1b Topline Results in Alzheimer's Disease
ImmunoBrain announced topline Phase 1b results for IBC-Ab002, a proprietary Fc-modified anti-PD-L1 antibody designed for transient peripheral immune checkpoint blockade in Alzheimer's disease. The approach is based on research by Prof. Michal Schwartz (Weizmann Institute) demonstrating that brief modulation of systemic immune tolerance can enhance clearance of brain pathology through recruitment of monocyte-derived macrophages. The Fc modification is engineered to avoid the sustained immune activation that drives autoimmune toxicity with oncology-dose checkpoint inhibitors—a critical design constraint for a chronic neurodegenerative indication. The oral presentation is scheduled for March 19.
Herantis Pharma: HER-096 Phase 1b in Parkinson's Disease
Herantis Pharma announced Phase 1b results in 24 Parkinson's disease patients for HER-096, a first-in-class CDNF-mimetic peptide designed to modulate the unfolded protein response (UPR) pathway and reduce α-synuclein aggregation. The oral-presentation data (March 18) showed all primary and secondary endpoints were met, with evidence of target engagement and acceptable tolerability. HER-096 represents a mechanistically distinct approach to PD that targets cellular stress pathways upstream of protein aggregation, rather than the aggregated protein itself. Herantis plans to advance to Phase 2 in 2026.
Additional AD/PD 2026 Presentations
CervoMed presented new analyses from the RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies (DLB), showing statistically significant slowing of clinical progression in DLB patients without Alzheimer's co-pathology---a finding that sharpens the drug's positioning for a potential registrational study in a purer DLB population. Vanqua Bio presented interim Phase 1 results for VQ-101 showing sustained greater than 50% activation of lysosomal GCase in GBA-Parkinson's patients, exceeding the pre-specified target engagement threshold. Annovis Bio provided an enrollment update for its pivotal Phase 3 buntanetap trial in early Alzheimer's disease alongside biomarker data from a Parkinson's study.
Aspen Neuroscience: ASPIRO 12-Month Parkinson's Cell Therapy Data (Late-Breaking)
On March 18, 2026, Aspen Neuroscience announced positive 12-month data from the Phase 1/2a ASPIRO trial of sasineprocel (ANPD001), an autologous iPSC-derived dopaminergic neuron cell therapy for Parkinson's disease, in a late-breaking oral presentation at AD/PD 2026. All eight treated patients showed improvements in symptom control, motor function, and quality of life at 12 months. Brain imaging confirmed that transplanted cells had successfully engrafted and remained alive at one year—critically, without requiring immunosuppression, since the cells are derived from each patient's own skin cells. Some patients reduced their levodopa dosage. Aspen is planning a Phase 3 trial later in 2026. The ASPIRO data represent one of the most significant cell therapy readouts in neurodegenerative disease to date and position Aspen as a potential licensing or partnering target for large pharma companies seeking regenerative medicine platforms.
Additional AD/PD 2026 Presentations
IRLAB Therapeutics presented Phase IIb REACT-PD results for pirepemat on falls frequency in Parkinson's disease, alongside preclinical data on AI/ML-driven drug discovery and amantadine for dyskinesias. ProMIS Neurosciences presented two posters on rational vaccine design targeting toxic misfolded TDP-43 (relevant to ALS/FTD) and alpha-synuclein conformers in Parkinson's disease. Brenig Therapeutics presented Phase 1 data for BT-267, a LRRK2 inhibitor for Parkinson's disease, and provided updates on BT-409, an NLRP3 inhibitor program for neuroinflammatory conditions.
ISICEM 2026: Sobi / HISS EMBRACE Phase 2a Data in Interferon-Gamma-Driven Sepsis
On March 18, 2026, Sobi (STO: SOBI) announced the presentation of detailed results from the Phase 2a EMBRACE study (NCT06694701) evaluating Gamifant (emapalumab) in patients with interferon-gamma (IFNγ)-driven sepsis (IDS) at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels. The presentation by Professor Evangelos J. Giamarellos-Bourboulis, President of the Hellenic Institute for the Study of Sepsis (HISS), marked the first public disclosure of quantitative efficacy data from the trial---supplementing the January 7, 2026 topline announcement that had described only directional proof-of-concept findings.
Key Efficacy Results
| Endpoint | High-Dose Emapalumab + SOC | Placebo + SOC |
|---|---|---|
| Primary: Improvement in organ function (≥1.4-point SOFA decrease at Day 28) | 60% | 40% |
| 28-day mortality | 40% | 52% |
| Biomarker response | Faster reduction in pro-inflammatory biomarkers linked to IFNγ signalling | --- |
Mechanism and Trial Design
Emapalumab is a monoclonal antibody that binds to and neutralizes IFNγ, already approved in the U.S. for primary hemophagocytic lymphohistiocytosis (HLH) and HLH/macrophage activation syndrome (MAS) in Still's disease. The EMBRACE study represents a precision medicine approach to sepsis---rather than treating all sepsis patients with a single immunomodulatory strategy, the trial selected patients with the IDS endotype, characterized by elevated CXCL9 and detectable IFNγ levels, representing approximately 20% of sepsis patients and associated with 28-day mortality rates of 40-43% in observational studies. The trial was a double-blind, randomized controlled study conducted at 24 sites in Greece, enrolling 75 patients across three arms: high-dose emapalumab plus standard of care, low-dose emapalumab plus standard of care, and placebo plus standard of care.
The IDS endotype concept builds on the work of HISS, which has established a track record of precision immunotherapy trials in sepsis through the SAVE-MORE trial (anakinra in COVID-19, published in Nature Medicine 2021) and the ImmunoSep trial (published in JAMA 2025), both of which demonstrated that biomarker-guided patient selection can identify subgroups that benefit from targeted immune modulation.
Strategic Implications
The 12-percentage-point absolute reduction in 28-day mortality (40% vs. 52%) in the high-dose arm—in a population with expected mortality exceeding 40%—is clinically meaningful if confirmed in a larger trial. Sobi has indicated it is discussing next clinical development steps with regulatory authorities, suggesting a potential Phase 2b or registrational study is under consideration. If emapalumab secures a sepsis indication, it would represent a significant commercial expansion for Gamifant beyond its current ultra-orphan HLH franchise (which generated approximately SEK 1.8 billion in 2024 sales). The sepsis market, with approximately 1.7 million cases annually in the U.S. alone and no approved targeted immunotherapies, represents a substantially larger commercial opportunity—though the history of failed sepsis drug development programs (including Eli Lilly's Xigris, withdrawn in 2011) provides a cautionary backdrop.
For dealmakers, the EMBRACE data add to the W12 theme of precision medicine approaches generating positive signals in historically intractable indications. The biomarker-guided endotyping approach—selecting the 20% of sepsis patients with IDS rather than treating the heterogeneous sepsis population—mirrors the broader industry trend toward companion diagnostic-driven patient selection that has transformed oncology deal structures and is now extending into immunology and critical care.
EAU 2026 Congress: Practice-Changing Urology Data
The final days of the European Association of Urology 2026 congress (March 13-16, London) produced several datasets with immediate implications for urological practice and the commercial landscape.
PRIMARY2 Trial: PSMA PET/CT Reduces Biopsy Burden
The PRIMARY2 trial, a Phase III randomized controlled study of 660 patients published in The Lancet Oncology, demonstrated that PSMA PET/CT safely halved the need for prostate biopsies (49% reduction) in men with normal or equivocal MRI but elevated clinical risk of cancer, without missing clinically significant cancers. The trial validates PSMA PET/CT as a triage tool upstream of biopsy, potentially reshaping the prostate cancer diagnostic pathway and expanding the addressable market for PSMA imaging agents.
Clarity Pharmaceuticals: 64Cu-SAR-bisPSMA Phase II Head-to-Head Data
Clarity Pharmaceuticals (ASX: CU6) presented Phase II head-to-head comparison data showing its copper-64-labeled SAR-bisPSMA PET agent detected 2.6 times more lesions than standard-of-care gallium-68 PSMA-11 in biochemical recurrence post-prostatectomy. The manuscript was simultaneously accepted by European Urology. The company's Phase III AMPLIFY trial reached target enrollment on March 9, with topline results expected in 2027. If confirmed in Phase III, the superior lesion detection could position SAR-bisPSMA as the next-generation standard for PSMA imaging.
Johnson & Johnson: Erdafitinib Intravesical Drug-Release System (Erda-iDRS)
J&J presented Phase 1 data for its intravesical drug-release system delivering erdafitinib (Balversa) directly into the bladder for FGFR-altered non-muscle-invasive bladder cancer (NMIBC). In 62 patients with intermediate-risk disease, the system achieved an 89% complete response rate and 83% 12-month recurrence-free survival in the high-risk cohort. The iDRS technology allows sustained local drug exposure while minimizing systemic toxicity---a meaningful advance for a population where standard intravesical BCG therapy fails in approximately 40% of patients. J&J plans to advance into the Phase 2/3 MoonRISe program.
Additional EAU 2026 Data
Prokarium presented interim Phase 1/1b PARADIGM-1 data for ZH9, a bacterial immunotherapy candidate for non-muscle-invasive bladder cancer (NMIBC), in an oral presentation at EAU. The EMBARK 5-year data update for enzalutamide in high-risk biochemically recurrent prostate cancer demonstrated 87.3% 5-year metastasis-free survival for the combination arm versus 71.4% for leuprolide alone (HR 0.42)---reinforcing the treatment intensification paradigm in early prostate cancer. Aura Biosciences discussed Phase 1 AU011 virus-like drug conjugate data showing 4 of 5 complete responses in intermediate-risk NMIBC target lesions. J&J additionally presented TAR-200 tissue penetration data demonstrating gemcitabine metabolite delivery across all bladder wall layers, supporting the intravesical drug-release platform's application across NMIBC subtypes.
AI-Native Discovery and Platform Partnerships
Roche and NVIDIA: Pharma's Largest AI Factory
On March 16, 2026, at NVIDIA's GTC conference, Roche announced the deployment of 2,176 new on-premise NVIDIA Blackwell GPUs across U.S. and European facilities, bringing its combined footprint above 3,500 Blackwell GPUs---the largest announced GPU deployment in the pharmaceutical industry.
Scope and Architecture
The "hybrid-cloud AI factory" spans four core domains: drug discovery (via BioNeMo and Lab-in-the-Loop workflows), manufacturing (Omniverse digital twins for a GLP-1 agonist production facility in North Carolina), diagnostics (Parabricks for GPU-accelerated genomics), and digital pathology. Roche's Genentech division reported that nearly 90% of eligible small-molecule programs now integrate AI in some capacity, with specific proof points including an oncology degrader molecule designed 25% faster than traditional timelines and a backup molecule delivered in 7 months versus an expected 2+ year cycle.
Strategic Context
Roche's announcement directly positions it against Eli Lilly's LillyPod---the first fully pharma-owned AI factory, powered by 1,016 NVIDIA Blackwell Ultra GPUs---and signals an emerging arms race among top-five pharma companies for computational infrastructure. While Lilly's $1 billion, 5-year NVIDIA co-innovation lab (announced at JPM 2026) is concentrated on drug discovery, Roche's deployment extends into manufacturing and diagnostics, reflecting its vertically integrated pharma-diagnostics business model. The question for the industry is no longer whether to invest in AI infrastructure but how aggressively to scale it.
Viva Biotech and NVIDIA: Lab-in-the-Loop Drug Discovery at GTC 2026
On March 16, 2026, at NVIDIA's GTC conference, Viva Biotech (01873.HK) showcased a collaboration with NVIDIA to accelerate AI-driven drug discovery using the newly released Proteina-Complexa model, a generative AI system for protein binder design released as part of NVIDIA's BioNeMo platform.
The collaboration focuses on designing mini-binders targeting ActRIIA (activin receptor type IIA), a transmembrane receptor in the TGF-β superfamily that plays a central role in the regulation of muscle mass and lean body composition. ActRIIA is a validated therapeutic target: luspatercept (Reblozyl, Bristol Myers Squibb/Merck), an ActRIIA ligand trap, is already marketed for anemia in myelodysplastic syndromes, and the broader activin/myostatin pathway has attracted significant pharmaceutical interest for indications ranging from sarcopenia and cachexia to muscular dystrophies.
Viva Biotech's approach leverages its "Lab-in-the-Loop" workflow---combining de novo computational protein design with high-throughput protein production and biophysical evaluation. The AI generates candidate binder sequences in silico; these are then rapidly synthesized, expressed, and tested in Viva's wet laboratory infrastructure; and the experimental results are fed back to refine the computational model in iterative cycles that progressively improve binding affinity, selectivity, and developability.
While the Viva Biotech/NVIDIA collaboration does not include disclosed financial terms, it represents an important category of partnership that is increasingly common in 2026: platform-level technology integrations where the "deal currency" is access, data, and validation rather than upfront payments and milestone structures.
NVIDIA Proteina-Complexa and BioNeMo Platform Expansion
The Proteina-Complexa model, released at GTC 2026, represents a significant advance in generative protein design. The model demonstrated validated binder generation against over 127 targets with binding affinities as tight as 93.6 pM, and was published as an ICLR 2026 Oral Presentation with collaborators from Duke University, Cambridge, LMU Munich, and Seoul National University. Early adopters announced at GTC include Novo Nordisk, Manifold Bio, and Viva Biotech.
Manifold Bio and NVIDIA: Million-Scale Protein Binder Validation
Manifold Bio announced results from a joint study using its mDesign platform to experimentally validate Proteina-Complexa outputs at unprecedented scale: one million binder designs tested against 127 targets in a single multiplexed experiment, measuring over 100 million protein-protein interactions and identifying specific binders to 68% of targets tested. This scale of wet-lab validation of computationally designed proteins is orders of magnitude beyond previous benchmarks and demonstrates the convergence of AI-driven design with high-throughput experimental platforms.
AlphaFold Database Expansion: 1.7 Million Protein Complex Predictions
NVIDIA, Google DeepMind, EMBL-EBI, and Seoul National University announced a massive expansion of the AlphaFold Protein Structure Database with approximately 30 million protein complex predictions calculated, of which 1.7 million high-confidence predictions were added to the public database. This represents the largest dataset of protein complex predictions currently available, prioritizing proteins important for human health and WHO priority pathogens. The dataset provides foundational structural data for target identification and drug design across the industry.
Additional GTC 2026 Healthcare AI Announcements
NVIDIA released nvQSP, a GPU-accelerated quantitative systems pharmacology simulation engine delivering up to 77-fold faster performance versus traditional single-threaded CPU simulations, enabling clinical trial simulation across hundreds of dose levels and patient subpopulations. Dassault Systèmes and NVIDIA showcased biology and therapeutics virtual twins using BioNeMo and BIOVIA world models. The GTC Taiwan Demo Day (March 17) featured CancerFree Biotech (Tim Draper-backed) demonstrating AI-driven lab automation for personalized cancer treatments. Cosmo Pharmaceuticals presented real-time medical AI for colonoscopy polyp detection on NVIDIA hardware (March 19).
IQVIA: IQVIA.ai Agentic Platform Powered by NVIDIA
IQVIA unveiled IQVIA.ai at GTC 2026, a unified agentic AI platform built on NVIDIA Nemotron and NeMo, featuring more than 150 specialized AI agents for life sciences workflows. The platform has been adopted by 19 of the top 20 pharmaceutical companies. For Capital for Cures and other data infrastructure providers, the IQVIA.ai launch is competitively significant: it represents a major incumbent's attempt to embed agentic AI across clinical development, commercial analytics, and regulatory operations.
Basecamp Research: Trillion Gene Atlas Initiative
Basecamp Research announced the Trillion Gene Atlas initiative at GTC 2026, a collaboration with Anthropic, Ultima Genomics, and PacBio aimed at expanding known evolutionary genetic diversity 100-fold using NVIDIA Parabricks for GPU-accelerated genomic analysis. The atlas is designed to provide foundational training data for next-generation protein design models and drug discovery platforms.
NVIDIA Healthcare Robotics and Additional BioNeMo Expansions
NVIDIA announced a comprehensive healthcare robotics platform comprising Open-H (700+ hours of surgical video data), Cosmos-H (synthetic surgical data generation), GR00T-H (vision-language-action clinical model), and Rheo (hospital digital twin framework). Additional BioNeMo platform expansions included RNAPro for RNA structure prediction, ReaSyn v2 for retrosynthesis, and nvMolKit for molecular property prediction.
TerraPower Isotopes: $450 Million Actinium-225 Production Facility
On March 17, 2026, TerraPower Isotopes (founded by Bill Gates) committed $450 million to build a 250,000 sq ft cGMP actinium-225 production facility at Philadelphia's Bellwether District, with production beginning in 2029 and approximately 225 jobs. Combined with an expanded Everett, WA facility, this will increase Ac-225 production approximately 20-fold. Pennsylvania is investing $10 million in supporting infrastructure. Actinium-225 is the critical isotope for targeted alpha therapy (TAT) radiopharmaceuticals, a rapidly expanding therapeutic modality attracting significant pharmaceutical investment from AstraZeneca, Bristol Myers Squibb, Eli Lilly, and Novartis. The TerraPower facility directly complements Bicycle Therapeutics' radiopharmaceutical supply chain strategy (detailed below) and addresses one of the most significant bottlenecks in the radiopharmaceutical value chain: isotope supply.
Licensing and Asset Transactions
Egret Therapeutics and Genexine: Non-Binding MOU for EGT-101 (GX-P1) Asset Transfer
On March 16, 2026, Egret Therapeutics announced the signing of a non-binding Memorandum of Understanding (MOU) with Genexine, Inc. (KOSDAQ: 095700) to acquire full right, title, and interest in its lead asset, GX-P1 (also known as EGT-101).
Mechanism and Clinical Context
EGT-101 is a first-in-class PD-L1-hyFc fusion protein designed for single-dose immune modulation following ischemic and traumatic injury. By selectively engaging PD-1 on circulating monocytes before they infiltrate injured tissue, EGT-101 is designed to reprogram these cells from an inflammatory state to a restorative phenotype---potentially preserving tissue structure and enabling functional recovery. In preclinical models, PD-L1 treatment significantly reduced malignant cerebral edema, preserved neurological function, and improved survival. EGT-101 has completed a Phase 1a clinical trial in healthy volunteers with no dose-limiting toxicities and favorable pharmacokinetics. A Phase 1b/2a trial in malignant cerebral edema following large vessel occlusion (MCE-LVO) stroke is in preparation.
The lead indication is Malignant Cerebral Edema following Large Vessel Occlusion Stroke (MCE-LVO), a devastating complication where secondary inflammatory cascades cause massive brain swelling after the initial ischemic event.
Deal History and Terms
The MOU builds on a 2021 definitive license agreement between Turret Capital (Egret's parent) and Genexine, under which Egret obtained global rights to GX-P1 for selective indications. The original 2021 deal terms included:
| Term | Detail |
|---|---|
| Upfront | Genexine received 5% of Egret Therapeutics outstanding common shares (~1 million shares) |
| Development and commercial milestones | Up to $200 million |
| Sublicensing milestones | Up to $1.5 billion (triggered if Egret sublicenses to third parties) |
Under the March 2026 MOU (signed March 6, 2026; announced March 16), the parties intend to transition Egret's exclusive global license into an outright asset transfer, granting Egret sole ownership of EGT-101 and all related intellectual property and materials. Financial terms of the proposed transfer were not disclosed. The MOU is non-binding and subject to execution of a definitive agreement; it should be treated as a process milestone rather than a closed transaction.
Strategic Implications
The license-to-ownership conversion eliminates future milestone and sublicensing payment obligations to Genexine, simplifying Egret's IP structure and giving the company full flexibility for future partnering or out-licensing. Egret describes a potential $45+ billion global market opportunity across neurological, cardiovascular, and traumatic indications. The deal adds to the W12 pattern of cross-border licensing from South Korea (alongside the Sentynl/PRG S&T deal for progerinin), and the stroke indication creates a thematic connection to VST BIO's $45 million philanthropically funded Series A for its VB-001 vascular leak program. Both Egret and VST BIO are pursuing novel approaches to post-ischemic secondary injury—Egret via immune modulation, VST BIO via vascular permeability—in a therapeutic space (acute stroke) that has seen minimal pharmacological innovation beyond the reperfusion window.
Sentynl Therapeutics and PRG S&T: Progerinin License for Progeria
On March 16, 2026, Sentynl Therapeutics announced a licensing agreement with PRG S&T, a South Korean company specializing in rare genetic disease therapies, to acquire rights to Progerinin (SLC-D011), an investigational oral small-molecule treatment for Hutchinson-Gilford Progeria Syndrome (HGPS). Sentynl is a wholly owned subsidiary of Zydus Lifesciences Limited (NSE: ZYDUSLIFE), a major Indian pharmaceutical company.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | PRG S&T (South Korea) |
| Licensee | Sentynl Therapeutics (Solana Beach, CA; subsidiary of Zydus Lifesciences) |
| Asset | Progerinin (SLC-D011), oral small molecule |
| Indication | Hutchinson-Gilford Progeria Syndrome (HGPS) |
| Structure | License with milestone-contingent full rights acquisition |
| Financial terms | Not disclosed (no upfront, milestones, or royalties quantified in the release); given the ultra-orphan indication (~400 patients worldwide), economics are likely structured around milestone payments tied to regulatory approvals and modest royalties rather than blockbuster-scale upfronts |
| Regulatory status | FDA Orphan Drug Designation; Phase 2A clinical trial finalizing, data expected by end of H1 2026 |
Under the agreement, Sentynl will collaborate with PRG S&T immediately to advance clinical development. If certain undisclosed milestones are met, Sentynl will acquire full rights to the molecule for HGPS upon closing---converting the license into an outright asset transfer, a structure conceptually similar to the Egret/Genexine MOU described above.
Mechanism and Clinical Context
HGPS is an ultra-rare, fatal genetic disorder affecting approximately 1 in 4 million births, caused by a point mutation in the LMNA gene that produces progerin, an aberrant form of the lamin A nuclear envelope protein. Progerin accumulates in cell nuclei, disrupting nuclear architecture, chromatin organization, and DNA repair mechanisms, leading to dramatically accelerated aging. Children with HGPS develop atherosclerosis, skeletal dysplasia, lipodystrophy, and scleroderma-like skin changes, with a mean age of death of approximately 14.5 years---predominantly from cardiovascular complications.
Progerinin operates through a mechanistically distinct pathway from Sentynl's existing HGPS therapy. Zokinvy (lonafarnib), the only FDA-approved treatment for progeria (approved 2020), is a farnesyltransferase inhibitor that works upstream---preventing the farnesylation of prelamin A and reducing progerin accumulation at the post-translational processing stage. Progerinin works downstream---selectively binding to the C-terminal region of progerin after it has been produced, disrupting its pathological interaction with wild-type lamin A, and promoting progerin degradation while sparing normal lamin A, B, and C proteins.
In preclinical studies published in Communications Biology, progerinin extended average lifespan in homozygous LmnaG609G/G609G progeria model mice from 16.8 weeks to 25.2 weeks (approximately 50% extension) and improved body weight, hair morphology, cardiac function, and histological phenotypes. A completed Phase 1 study in 63 healthy volunteers (NCT04512963) demonstrated an acceptable safety profile across all tested doses up to 2,400 mg, with no clinically significant drug-drug interaction potential.
Strategic and Market Implications
The Sentynl/PRG S&T deal is notable for several reasons beyond its rare disease focus:
Portfolio consolidation in ultra-orphan therapeutics. Sentynl acquired Zokinvy globally from Eiger BioPharmaceuticals in May 2024 for $45.2 million through a court-supervised Section 363 bankruptcy sale (Eiger's initial stalking horse bid was $26 million, but competitive bidding drove the final price significantly higher), making it the sole commercial therapy for HGPS. Notably, Eiger had originally licensed exclusive worldwide rights to lonafarnib for progeria from MSD (Merck), which waived all royalty and milestone obligations on the compound for the progeria indication---meaning Sentynl's Zokinvy economics are unencumbered by upstream royalty obligations. Adding Progerinin as a mechanistically complementary second agent creates a potential combination or sequential treatment strategy in a disease where the existing standard of care, while life-extending, does not approach a cure. The upstream (farnesylation blockade) plus downstream (progerin-lamin A binding inhibition) combination logic is scientifically compelling.
Zydus Lifesciences' growing rare disease footprint. Zydus (market cap approximately $15 billion) has historically been known as a generics and specialty pharma company focused on the Indian market. The Sentynl subsidiary---which also markets rare disease products beyond progeria---represents Zydus's strategic expansion into U.S.-centric orphan drug commercialization, a trend worth monitoring as Indian pharmaceutical companies increasingly seek higher-margin specialty portfolios.
Cross-border licensing from South Korea. The PRG S&T license adds to a steady stream of Korean biotech assets entering global development through licensing agreements, consistent with the broader pattern of Korean biotechnology companies generating novel clinical-stage molecules that are then out-licensed to companies with U.S. and European regulatory and commercial infrastructure.
Financial terms were not disclosed, limiting the deal's utility as a valuation benchmark. However, given the ultra-orphan indication (total addressable patient population estimated at approximately 400 children worldwide at any given time), the economics are likely structured around milestone payments tied to regulatory approvals and possibly modest royalties rather than blockbuster-scale upfronts.
R1 Therapeutics and Alebund Pharmaceuticals: AP306 Ex-China License and $77.5 Million Series A
On March 17, 2026, Alebund Pharmaceuticals announced a collaboration and license agreement with R1 Therapeutics, a newly launched clinical-stage biotech, granting R1 exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China. Concurrently, R1 closed an oversubscribed $77.5 million Series A co-led by Abingworth, DaVita Venture Group, and F-Prime Capital, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care.
Mechanism and Clinical Context
AP306 is a first-in-class pan-phosphate transporter inhibitor targeting hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis. Unlike conventional phosphate binders---which work passively in the gut lumen by chelating dietary phosphate and require high pill burdens (often 6-12 tablets daily)---AP306 inhibits the active transport of phosphorus through three key sodium-dependent phosphate transporters (NaPi-IIb, PiT-1, and PiT-2) in the gastrointestinal tract. This mechanistically distinct approach has the potential to deliver more effective phosphate lowering with a substantially reduced treatment burden.
Hyperphosphatemia affects the majority of dialysis patients and is associated with vascular calcification, cardiovascular mortality, and bone disease. Despite widespread use of phosphate binders (sevelamer, lanthanum carbonate, ferric citrate), approximately 40-50% of dialysis patients remain above target serum phosphate levels, reflecting both the limitations of binder efficacy and the compliance challenges of high pill burdens. The global phosphate binder market exceeds $2 billion annually, and a mechanistically superior approach with improved adherence could capture meaningful share.
AP306 was originally discovered by Chugai Pharmaceutical Co., Ltd. and subsequently licensed to Shanghai-based Alebund Pharmaceuticals under a 2021 option and license agreement. Alebund conducted a Phase 2a proof-of-concept study (NCT05764590) in 55 hemodialysis patients, with results published in Kidney International Reports demonstrating significant serum phosphate reduction with good safety and tolerability. AP306 has also received Breakthrough Therapy Designation from China's NMPA.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | Alebund Pharmaceuticals (Shanghai) |
| Licensee | R1 Therapeutics, Inc. (newly formed) |
| Asset | AP306, oral pan-phosphate transporter inhibitor |
| Indication | Hyperphosphatemia in CKD patients on dialysis |
| Licensed territory | Global ex-Greater China |
| Development, regulatory, and commercial milestones | Up to low triple-digit millions of U.S. dollars |
| Royalties | Tiered royalties in the low double-digit percentage range on net sales in the licensed territory |
| Equity component | Alebund holds a substantial non-dilutive equity interest in R1, with dividend participation rights |
| Development responsibilities | R1 funds and leads global clinical development; Alebund as collaborative development partner |
| Near-term clinical plan | Global Phase 2b multi-regional clinical trial (MRCT) in U.S. and China, initiation planned for H2 2026 |
| R1 Series A | $77.5 million (oversubscribed), co-led by Abingworth, DaVita Venture Group, and F-Prime Capital |
| R1 legal counsel | Wilson Sonsini Goodrich & Rosati |
Strategic and Royalty Implications
The R1/Alebund deal is notable for several reasons beyond its licensing economics:
Integrated investor-channel partner structure. DaVita (NYSE: DVA), one of the world's largest dialysis providers serving approximately 295,000 patients across 3,242 centers, and U.S. Renal Care, the largest privately held dialysis provider in the United States (37,000+ patients across 32 states), are both investors in R1 and operate the clinical infrastructure where AP306 would ultimately be prescribed. This creates a vertically integrated commercial pathway rare in early-stage biotech licensing: the investors who funded the company also control patient access in the largest addressable market. For royalty investors, this alignment between capital, clinical development, and commercial channels significantly de-risks the path to peak sales.
Royalty structure economics. The tiered low double-digit percentage royalties on ex-China net sales, combined with Alebund's equity stake and dividend participation, create a layered economic interest for the licensor. If AP306 achieves even modest penetration of the >$2 billion phosphate management market, the royalty stream alone could be material. The milestone payments (low triple-digit millions in aggregate) provide near-term value, while the equity interest gives Alebund upside participation in R1's enterprise value beyond the royalty economics.
Cross-border licensing from China. The deal adds to a growing pattern of Chinese biotech companies generating clinically validated assets that are then out-licensed to U.S.-centric companies for global development---mirroring the Korean licensing trend exemplified by the Sentynl/PRG S&T deal above. The Chugai-to-Alebund-to-R1 chain also illustrates the multi-hop licensing structures increasingly common in nephrology, where assets may pass through several hands before reaching the company best positioned for global registrational development.
Founder pedigree. R1 CEO Krishna Polu, M.D., previously co-founded Mineralys Therapeutics (now publicly traded) and Renalys Pharma (acquired by Chugai), establishing a track record of building nephrology-focused companies to successful exits---a relevant signal for investors evaluating the team's ability to execute through Phase 2b and beyond.
Astellas Pharma / CytomX Therapeutics: $1.6 Billion Collaboration Terminated
On March 16, 2026, CytomX Therapeutics disclosed that Astellas Pharma elected not to advance the remaining preclinical programs under their six-year Probody T-cell engager collaboration, effectively terminating the partnership as of Q2 2026.
Deal History and Financial Terms
The original 2020 collaboration included an $80 million upfront payment and up to $1.6 billion in potential milestone payments to discover and develop conditionally activated T-cell engagers using CytomX's Probody platform for solid tumor targets. CytomX was also eligible to receive tiered royalties on global net sales ranging from high-single digits to mid-teens percentages. For a specified number of targets, CytomX retained a cost-sharing and U.S. co-commercialization option prior to the initiation of the first pivotal trial. CytomX also received milestone payments of $10 million across March-April 2024 for two clinical candidate nominations before Astellas ultimately elected not to advance the remaining preclinical programs. The termination follows BMS's exit from the checkpoint inhibitor portion of its own CytomX collaboration in March 2024, which eliminated approximately $300 million in potential value.
Strategic Implications
The Astellas termination represents a significant headwind for CytomX's platform licensing strategy, eliminating the potential for substantial milestone revenues and raising questions about the broader market appetite for Probody-based bispecific T-cell engager programs. The lost royalty stream---high-single-digit to mid-teens percentages on global net sales---would have been material if any program had reached commercialization. For context, CytomX's other major platform deals include a $200 million upfront expanded collaboration with Bristol-Myers Squibb (with development, regulatory, sales milestones, and tiered royalties) and a $35 million upfront (including $5 million pre-paid research) collaboration with Regeneron (up to approximately $1.2 billion in future milestones). CytomX also has an Amgen collaboration with high-single-digit to mid-double-digit royalty payments on resulting products. However, CytomX's proprietary pipeline---particularly the encouraging Varseta-M EpCAM ADC data in colorectal cancer---provides an independent value driver. The company reported $281 million in cash as of year-end 2025, providing runway into 2028.
For the broader industry, the termination reflects continuing skepticism about the translatability of T-cell engager approaches in solid tumors, where the immunosuppressive tumor microenvironment has historically blunted efficacy relative to the dramatic responses seen in hematological malignancies.
Novartis / Synnovation Therapeutics: $3 Billion Acquisition of Pikavation (PI3Kα Inhibitor)
On March 20, 2026, Synnovation Therapeutics announced a definitive agreement for Novartis to acquire Pikavation Therapeutics, Inc., a wholly owned subsidiary of Synnovation, and its portfolio of pan-mutant selective PI3Kα inhibitor programs, including the lead asset SNV4818---a potentially best-in-class oral PI3Kα inhibitor currently in Phase 1/2 clinical trials for the treatment of HR+/HER2- metastatic breast cancer and other solid tumors.
Deal Structure
| Term | Detail |
|---|---|
| Acquirer | Novartis AG (SIX: NOVN) |
| Target | Pikavation Therapeutics, Inc. (wholly owned subsidiary of Synnovation) |
| Upfront payment | $2 billion in cash |
| Milestone payments | Up to $1 billion in development, regulatory, and commercial milestones |
| Total potential consideration | Up to $3 billion |
| Expected close | H1 2026, subject to HSR review and customary conditions |
| Target financial advisor | Centerview Partners LLC (exclusive) |
| Target legal counsel | Goodwin Procter LLP (team led by Samuel Beavers and Sarah Solomon); Mintz Levin |
| Retained by Synnovation | All other R&D subsidiaries, including SNV1521 (PARP1-selective inhibitor, Phase 1) |
Mechanism and Competitive Context
PI3Kα mutations (predominantly in the PIK3CA gene) are present in approximately 40% of HR+/HER2- breast cancer patients and represent one of the most common oncogenic drivers in the disease. SNV4818 applies new mutant-selective chemistry designed to inhibit the full spectrum of PI3Kα mutations while sparing the wild-type enzyme---a critical pharmacological distinction that could translate into improved tolerability relative to earlier-generation PI3Kα inhibitors. The Phase 1/2 trial is testing SNV4818 as both a monotherapy and in combination with AstraZeneca's Faslodex (fulvestrant) and Pfizer's Ibrance (palbociclib).
The competitive landscape in mutant-selective PI3Kα inhibition is intensifying. Novartis already markets Piqray (alpelisib), a first-generation PI3Kα inhibitor approved for PIK3CA-mutated HR+/HER2- breast cancer, but Piqray is limited by hyperglycemia and other on-target toxicities attributable to incomplete mutant selectivity. Roche's Itovebi (inavolisib), approved by the FDA in October 2024, is the first mutant-selective PI3Kα inhibitor on the market and is capturing share rapidly. Eli Lilly's tersolisib is advancing through clinical development. SNV4818's pan-mutant selectivity---covering a broader range of PIK3CA mutations than narrower-spectrum competitors---is the mechanistic differentiator that underpins the premium valuation.
Strategic and Deal Landscape Implications
The Novartis/Synnovation deal is the single largest transaction of W12 by total potential value and the first billion-dollar-plus M&A announcement in the window. Several aspects merit attention for dealmakers:
Defensive franchise protection. Novartis is paying a $2 billion upfront premium for a Phase 1/2 asset---an extraordinarily front-loaded deal structure for a clinical-stage program---in part to protect its existing PI3Kα franchise from competitive erosion by Roche's Itovebi and to secure a potential best-in-class successor to Piqray. The deal directly complements the Pfizer atirmociclib Phase 2 data (also reported in W12) that is reshaping the CDK4/6 inhibitor landscape in the same breast cancer population.
Synnovation's rapid value creation. Synnovation emerged with $102 million in financing in 2024 and initiated the Phase 1/2 trial approximately one year ago. The $2 billion upfront return on a ~$100 million investment in less than two years represents one of the highest-velocity value creation events in recent oncology deal history. Synnovation was founded by former Incyte scientists, including CEO Wenqing Yao, Ph.D.
Subsidiary acquisition structure (no royalty or CVR component). By acquiring Pikavation as a subsidiary rather than Synnovation itself, Novartis obtains the PI3Kα portfolio while leaving Synnovation free to continue advancing its other pipeline assets independently---a clean carve-out structure that preserves optionality for both parties. Notably, because this is structured as a full subsidiary acquisition rather than a license, there is no royalty, CVR, or ongoing payment stream from Novartis to Synnovation beyond the upfront and milestone consideration—all future economics flow entirely within Novartis.
Collegium Pharmaceutical / Corium Therapeutics: $785 Million AZSTARYS Acquisition
On March 19, 2026, Collegium Pharmaceutical (Nasdaq: COLL) and Corium Therapeutics Holdings announced a definitive agreement for Collegium to acquire AZSTARYS (serdexmethylphenidate/dexmethylphenidate), an FDA-approved treatment for ADHD in patients aged 6 and older, for $650 million in cash at closing plus up to $135 million in commercial and regulatory milestones---total potential consideration of up to $785 million.
Deal Structure
| Term | Detail |
|---|---|
| Buyer | Collegium Pharmaceutical, Inc. (Nasdaq: COLL) |
| Seller | Corium Therapeutics Holdings, LLC (privately held; affiliate of Gurnet Point Capital) |
| Asset | AZSTARYS (serdexmethylphenidate/dexmethylphenidate), FDA-approved ADHD treatment |
| Upfront consideration | $650 million in cash |
| Contingent milestones | Up to $135 million tied to commercial and regulatory milestones |
| Funding | Cash on hand + $300 million delayed-draw term loan (SOFR + 325 bps; part of December 2025 syndicated credit facility) |
| Patent protection | Six Orange Book-listed patents, most expiring December 2037 |
| Buyer financial advisor | Leerink Partners (exclusive) |
| Seller financial advisor | Centerview Partners (exclusive) |
| Buyer legal counsel | Goodwin Procter LLP |
| Seller legal counsel | Sullivan & Cromwell LLP |
| Expected close | Q2 2026, subject to HSR approval |
Commercial Context and Royalty Implications
AZSTARYS generated over 760,000 prescriptions in 2025 and is expected to produce more than $50 million in pro forma net revenue in H2 2026. Collegium expects over $50 million in annual synergies within 12 months and immediate adjusted EBITDA accretion. The acquisition complements Collegium's existing Jornay PM franchise in ADHD.
Critically for royalty investors, the AZSTARYS acquisition involved a hidden $50 million royalty buyout that cleared the cap table days before the Collegium announcement. On March 13, 2026---just three business days before the deal was disclosed---Commave Therapeutics (a Gurnet Point Capital affiliate that controls Corium) executed a $50 million asset purchase from Zevra Therapeutics (formerly KemPharm, the original AZSTARYS developer) to extinguish all royalty and milestone obligations under the 2019 license agreement. The $50 million was structured as $25 million upfront, $20 million within 10 business days, and $5 million upon record delivery. This simultaneously terminated the license and settled Delaware Chancery Court litigation (Commave had obtained a ruling that Zevra's pledge of the license as loan collateral violated ROFR/ROFN provisions). Zevra repaid its $63 million term loan in full on March 12, one day before the sale.
The original royalty economics were substantial: SEC-filed exhibits (partially redacted) show U.S. royalties were tiered from high-single digits (~8-9%) to mid-twenties (~24-25%) on aggregate annual net sales, with ex-U.S. royalties at low-to-mid single digits (~2-5%). An April 2021 amendment enhanced these rates and increased total milestone potential from $483 million to $590 million (sales milestones alone: $550 million). Aquestive Therapeutics held a sub-royalty of approximately 10-14% on all KemPharm/Zevra royalties and milestones under a 2012 agreement.
The net effect: Collegium acquired a royalty-free asset for $650 million plus $135 million in milestones, while GPC/Commave's effective net was approximately $600 million upfront after absorbing the $50 million buyout cost. This pre-transaction royalty extinguishment—executed days before the acquirer was publicly named—mirrors the Zevra/Commave SDX portfolio sale also closed in W12 and represents the clearest example in the week of acquirers paying premiums for clean IP structures free of third-party royalty obligations.
Corium Therapeutics is an affiliate of Gurnet Point Capital, an investment firm. Florida-based prodrug specialist KemPharm (now Ligand Pharmaceuticals) originally secured FDA approval for AZSTARYS in 2021, two years after licensing the product to Corium in 2019.
CytomX Therapeutics: $250 Million Underwritten Public Offering
On March 18, 2026, CytomX Therapeutics (NASDAQ: CTMX) priced a $250 million underwritten public offering of common stock and pre-funded warrants---the largest pure equity financing event in the W12 window (excluding the CRISPR Therapeutics convertible note and the Paratek-Radius debt package).
Deal Structure
| Term | Detail |
|---|---|
| Issuer | CytomX Therapeutics, Inc. (NASDAQ: CTMX) |
| Instrument | Underwritten public offering of common stock and pre-funded warrants |
| Gross proceeds | $250 million (before underwriting discounts and offering expenses) |
| Common shares | 45,990,000 shares at $5.30 per share |
| Pre-funded warrants | 1,179,245 warrants at $5.2999 per warrant; exercise price $0.0001 |
| Overallotment | 30-day option for up to 7,075,471 additional shares (~$37.5 million) |
| Joint book-running managers | Jefferies, Piper Sandler, Cantor, Barclays |
| Co-manager | Wedbush PacGrow |
| Expected close | March 19, 2026 |
| Use of proceeds | Varseta-M (EpCAM Probody ADC) development through potential registrational study; nuzefatide pevedotin (BT5528-equivalent EphA2 BDC); pipeline advancement; working capital |
Strategic Context
The offering was announced on March 16---the same day CytomX disclosed both the Astellas collaboration termination and the encouraging Varseta-M Phase 1 expansion data in colorectal cancer. The timing was not coincidental: with the $1.6 billion biobucks partnership unwinding, CytomX moved immediately to capitalize on the positive Varseta-M data (32% confirmed ORR, ~90% disease control rate) to raise non-dilutive-alternative capital. The four-bank underwriting syndicate (Jefferies, Piper Sandler, Cantor, Barclays) reflects institutional confidence in CytomX's proprietary pipeline despite the Astellas headwind. Combined with the company's $281 million in existing cash (year-end 2025), the $250 million offering provides runway into 2028+ for the Varseta-M registrational path and the broader Probody platform.
For the T-cell engager landscape, the CytomX offering bookends a striking W12 trifecta: the Astellas termination (reflecting skepticism about conditional T-cell engagers in solid tumors), the Crossbow Therapeutics $77 million Series B (validating TCR-mimetic T-cell engager approaches in myeloid cancers), and Excalipoint Therapeutics' $68.7 million seed launch in China (confirming sustained global appetite for next-generation TCE platforms). The competitive dynamics in this space are shifting rapidly.
PCI Biotech Holding: Company Dissolution Approved
On March 16, 2026, an extraordinary general meeting approved the dissolution and delisting of PCI Biotech Holding ASA (Oslo: PCIB). The company had discontinued all R&D operations in its photochemical internalization (PCI) drug delivery platform in January 2026 and entered a structured wind-up process. The dissolution was approved unanimously by attending shareholders. PCI Biotech had previously explored licensing partnerships for its fimaporfin-based endosomal escape technology but was unable to secure a viable commercial path.
Fulgent Genetics: $56.9 Million Acquisition of Bako Diagnostics and StrataDx
On March 17, 2026, Fulgent Genetics (NASDAQ: FLGT) announced the completion of its acquisition of Bako Diagnostics and StrataDx, as previously announced on December 22, 2025.
Deal Structure
| Term | Detail |
|---|---|
| Buyer | Fulgent Genetics, Inc. (NASDAQ: FLGT), via subsidiary Inform Diagnostics, Inc. |
| Targets | Bako Diagnostics (Alpharetta, GA; substantially all assets and certain liabilities); StrataDx (Lexington, MA; 100% equity acquisition) |
| Seller / controlling shareholder | Consonance Capital Partners (healthcare-focused PE) |
| Total consideration | $56.9 million cash (subject to post-closing adjustments) |
| Bako component | Base purchase price: $43.0 million (asset purchase agreement) |
| StrataDx component | Base purchase price: $12.5 million (equity acquisition) |
| Original announced consideration | $55.5 million (December 2025); adjusted to $56.9 million at closing |
| Buyer financial advisor | Piper Sandler & Co. (exclusive) |
| Buyer legal counsel | Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| Seller financial advisor | EV Health Partners (exclusive) |
| Seller legal counsel | Latham & Watkins LLP |
| Buyer investor relations | The Blueshirt Group |
| SEC filing | Form 8-K filed March 17, 2026 |
Strategic Context
Bako Diagnostics is a national specialty laboratory offering complete anatomic pathology services, proprietary molecular genetic (PCR) testing, and peripheral neuropathy immunohistochemical testing. StrataDx is a national dermatopathology laboratory considered a market leader in dermatology testing. Both are CLIA-certified and CAP-accredited.
The acquisition advances Fulgent's strategy to build a fully integrated precision medicine platform spanning laboratory services and therapeutic development. Fulgent highlighted three specific synergy vectors: (1) AI-powered digital pathology through its proprietary Eziopath image management system, (2) test menu expansion via Bako's proprietary PCR assays, and (3) commercial synergies from Bako's and StrataDx's nationwide sales infrastructure. Consonance Capital, a healthcare-focused PE firm, had partnered with Bako's management team for approximately a decade. No royalty or licensing components are embedded in this transaction; it is a clean asset/equity acquisition paid from Fulgent's cash on hand.
Zevra Therapeutics: $50 Million SDX Portfolio Sale to Commave Therapeutics
On March 16, 2026, Zevra Therapeutics (NasdaqGS: ZVRA) announced the sale of its entire serdexmethylphenidate (SDX) portfolio to Commave Therapeutics SA for $50 million, concurrently settling Delaware Chancery Court litigation and terminating a 2019 license agreement.
Deal Structure
| Term | Detail |
|---|---|
| Seller | Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) |
| Buyer | Commave Therapeutics SA (Switzerland) |
| Assets transferred | Entire SDX portfolio: AZSTARYS (serdexmethylphenidate/d-methylphenidate, FDA-approved for ADHD) and KP1077 (serdexmethylphenidate for idiopathic hypersomnia) |
| Purchase price | $50 million cash: $25 million upfront; $20 million within ten business days; $5 million upon delivery of specified records |
| Agreement type | Asset Purchase and Settlement Agreement (signed March 13, 2026; announced March 16, 2026) |
| Prior license | 2019 exclusive license agreement granting Commave rights to certain SDX products---terminated as part of the transaction |
| Litigation settlement | Delaware Chancery Court case C.A. No. 2024-0920-LWW (initiated by Commave in 2024)---mutual settlement and dismissal |
| License-back | Zevra grants Commave a worldwide, royalty-free, fully paid-up, transferable, perpetual license (with sublicensing rights) under Zevra-retained patents and know-how for SDX products |
| Debt paydown | Zevra separately repaid its $63 million term loan in full on March 12, 2026 (prior to entering the asset sale), terminating the 2024 senior secured credit agreement and releasing all liens |
| SEC filing | Form 8-K filed March 16, 2026 |
| Advisors / counsel | Not disclosed in the filing or press release for the asset sale transaction |
Licensing and Royalty Implications
The Zevra/Commave transaction illustrates the full lifecycle of a licensing relationship: initial license (2019), dispute (2024 Delaware litigation), and resolution via outright asset sale with perpetual license-back (2026). The license-back structure---worldwide, royalty-free, perpetual, with sublicensing rights---effectively severs all future royalty and milestone obligations between the parties while giving Commave clean title to the SDX assets. For royalty investors, this deal eliminates any future royalty stream from Zevra's SDX portfolio; Commave now owns the assets outright and Zevra retains no economic interest beyond the $50 million purchase price.
AZSTARYS is an FDA-approved treatment for ADHD that was previously commercialized by Corium (Zevra's commercial partner) and generated royalty income for Zevra. The sale converts a recurring royalty stream into a one-time cash payment---a strategic choice that reflects Zevra's decision to concentrate resources on its rare disease franchise (MIPLYFFA for Niemann-Pick disease type C). The $63 million debt repayment, combined with the $50 million asset sale proceeds, leaves Zevra with a debt-free balance sheet and substantially enhanced financial flexibility for its NPC-focused strategy.
Bicycle Therapeutics: Strategic Reprioritization and 30% Workforce Reduction
On March 17, 2026, Bicycle Therapeutics (NASDAQ: BCYC) announced a strategic reprioritization of its clinical portfolio, including a proposed 30% workforce reduction (approximately 86 roles) that is expected to halve annual operating expenses and extend cash runway from 2028 into 2030. The company reported $628 million in cash as of December 31, 2025.
Pipeline Restructuring
The restructuring was triggered by regulatory feedback indicating that the existing Duravelo-2 Phase II/III registrational trial design was no longer considered an acceptable approval pathway for zelenectide pevedotin in metastatic urothelial cancer (mUC). Although dose selection data were promising---physician-assessed ORR of 65% and blinded independent central review ORR of 58% at the 27-week cutoff with a differentiated safety profile---Bicycle will convert Duravelo-2 from a Phase II/III registrational trial to a randomized Phase II study, discontinue the Duravelo-3 (breast cancer) and Duravelo-4 (NSCLC) trials for zelenectide, and cease internal development of BT7480 (a Nectin-4-targeted CD137 agonist) while seeking a partner for future development.
The company is refocusing on nuzefatide pevedotin (BT5528), a potential first-in-class EphA2-targeting Bicycle Drug Conjugate (BDC) that began enrolling a Phase 2 trial in recurrent pancreatic ductal adenocarcinoma in March 2026, and its emerging Bicycle Radioconjugate (BRC) portfolio. Bicycle recently established strategic partnerships with the UK Nuclear Decommissioning Authority (15-year contract for access to up to 400 tonnes of reprocessed uranium), the UK National Nuclear Laboratory (for 228Th extraction scale-up), and SpectronRx (for 212Pb generator development)---building an end-to-end isotope-agnostic supply chain for radiopharmaceutical development.
For dealmakers, the BT7480 partnering opportunity and the broader question of whether Bicycle's proprietary bicyclic peptide platform can generate next-generation oncology therapeutics with improved benefit/risk profiles are the key items to monitor. The $628 million cash position and 2030 runway provide substantial flexibility for potential licensing or collaboration deals.
Gossamer Bio: Phase 3 PROSERA Failure Aftermath and 48% Workforce Reduction
On March 17, 2026, Gossamer Bio (NASDAQ: GOSS) announced a 48% workforce reduction (approximately 77 roles) following the Phase 3 PROSERA trial failure of seralutinib in pulmonary arterial hypertension, announced in February 2026. The trial narrowly missed its primary endpoint (p=0.032 against a prespecified alpha of 0.025). The company is evaluating strategic options, including potential asset sales or partnerships. Shares had already fallen approximately 80% since the PROSERA miss.
XOMA Royalty's Seralutinib Economic Interest
XOMA Royalty holds economic interests in seralutinib through its $20 million acquisition of Pulmokine Inc. (completed November 2024), which held the original royalty and milestone interest retained when Pulmokine licensed seralutinib to Gossamer Bio in 2017. Under this arrangement, XOMA receives low-to-mid single-digit net royalties on commercial sales and retains up to $25 million from milestone payments, with additional contingent success-based consideration payable to former Pulmokine shareholders. The underlying commercial economics flow from the Gossamer Bio/Chiesi Group collaboration (May 2024), which provided Gossamer with $160 million in development reimbursement from Chiesi, up to $146 million in regulatory milestones, up to $180 million in sales milestones, a 50/50 U.S. profit split, and escalating mid-to-high teens percentage ex-U.S. royalties from Chiesi to Gossamer. The PROSERA failure and Gossamer's restructuring significantly impair the near-term value of XOMA's seralutinib position, though Gossamer is evaluating whether a path forward exists for the asset. For royalty investors, the XOMA/Pulmokine/Gossamer chain illustrates both the potential and the risk of acquiring royalty interests in Phase 3 assets—XOMA paid $20 million for economics on a drug that had peak-sales potential exceeding $1 billion, but the Phase 3 miss has materially reduced the probability-adjusted value of that investment.
Sarepta Therapeutics: Elevidys Sirolimus Safety Study Initiated
On March 16, 2026, Sarepta Therapeutics (NASDAQ: SRPT) announced the initiation of enrollment in ENDEAVOR Cohort 8, evaluating a prophylactic sirolimus-based immunosuppression regimen (14 days pre-infusion, 12 weeks post-infusion) alongside Elevidys (delandistrogene moxeparvovec) gene therapy in approximately 25 non-ambulatory Duchenne muscular dystrophy (DMD) patients. This cohort is designed to prevent the acute liver injury that caused two teenage deaths in 2024/2025 and led to FDA-imposed label restrictions limiting Elevidys to ambulatory patients only. Positive safety data could support a supplemental BLA to restore the non-ambulatory indication---a critical commercial expansion for a therapy that represents one of the most expensive single-dose treatments in medicine.
Elevidys Upstream Licensing and Royalty Structure
Elevidys originated from micro-dystrophin gene therapy research by Jerry Mendell, MD, and Louise Rodino-Klapac, PhD, at Nationwide Children's Hospital (NCH). Sarepta exercised an exclusive worldwide license from NCH in October 2018 under terms that include a $1.0 million upfront payment, development, regulatory, and sales milestones of up to $29 million per micro-dystrophin product, low-single-digit percentage royalties on net sales, and a tiered percentage of sublicense income. In July 2021, Sarepta's ex-U.S. collaboration with Roche triggered a $38 million sublicense settlement payment to NCH. A November 2021 amendment waived certain future milestone payments and altered royalty terms. Sarepta also earned approximately $66 million in 2024 from Roche's ex-U.S. commercialization through contract manufacturing and royalty revenue. For royalty investors, the NCH upstream interest represents a modest but commercially validated academic royalty stream on a gene therapy that generated $1.24 billion in FY2024 U.S. net revenue---making it one of the highest-revenue products with a disclosed academic royalty burden in the gene therapy space.
Financing and Capital Markets
CRISPR Therapeutics: $600 Million Convertible Senior Notes
On March 16, 2026, CRISPR Therapeutics (NASDAQ: CRSP) announced the closing of its upsized convertible senior notes offering, the largest single convertible financing event in the W12 window.
Deal Structure
| Term | Detail |
|---|---|
| Principal amount | $600M ($550M base + $50M overallotment exercised in full; upsized from initial $350M offering) |
| Maturity | March 1, 2031 |
| Effective coupon | 1.125% per annum (gross coupon: 1.7308%, reflecting a 0.6058% uplift to offset anticipated 35% Swiss withholding tax for non-refund-eligible holders) |
| Initial conversion price | ~$76.56/share (13.0617 shares per $1,000 principal; ~45% premium to $52.80 close on March 10) |
| Net proceeds | ~$585.2M |
| Placement | Rule 144A to qualified institutional buyers |
| Capped call transactions | Yes (to offset dilution up to ~$99.12/share) |
| Joint bookrunners | Leerink Partners (confirmed); additional initial purchasers not publicly named |
| Initial purchaser counsel | Davis Polk & Wardwell LLP |
| Issuer counsel | Goodwin Procter LLP |
| Trustee | U.S. Bank Trust Company, National Association |
| Optional redemption | On or after March 6, 2029 |
The offering represents a decisive move by CRISPR to lock in long-duration capital at an attractive coupon as it scales commercialization of Casgevy (exagamglogene autotemcel), the first CRISPR-based gene therapy approved by the FDA (December 2023) for sickle cell disease and transfusion-dependent beta-thalassemia. The 45% conversion premium and 1.125% coupon reflect strong institutional demand despite the stock trading well below its 2021 highs.
Paratek Pharmaceuticals and Radius Health: $1.3 Billion Debt-Financed Combination Closes
On March 18, 2026, Paratek Pharmaceuticals announced the completion of its combination with Radius Health, Inc., creating a scaled, multi-product specialty pharmaceutical company backed by B-FLEXION Life Sciences and financed with a $1.3 billion debt package led by Blackstone Credit & Insurance alongside co-investors Sixth Street, Oaktree Capital Management, Silver Point Capital, and Pharmakon Advisors. BioPharma Credit separately invested $100 million ($50 million directly, $50 million via BioPharma Credit Investments V) to replace a prior $25 million position in Paratek. Lazard acted as exclusive financial advisor to B-FLEXION and Paratek; Skadden, Arps served as legal advisor.
Combined Portfolio and Scale
| Product | Indication | Type |
|---|---|---|
| TYMLOS (abaloparatide) | Osteoporosis | Injectable PTHrP analog |
| NUZYRA (omadacycline) | Community-acquired bacterial pneumonia, skin infections | Oral/IV antibiotic |
| XHANCE (fluticasone propionate) | Chronic rhinosinusitis with or without nasal polyps | Nasal exhalation delivery system |
The combined company is expected to generate nearly $1 billion in annual revenue in 2026, reflecting the scale achieved through B-FLEXION's platform-building strategy since acquiring Paratek in 2023. The transaction is the largest single financing event in the W12 window by deal value, exceeding the CRISPR Therapeutics $600 million convertible note.
Strategic and Royalty Market Implications
The Paratek/Radius combination is significant for the pharmaceutical royalty and revenue interest market for several reasons:
Revenue interest financing structure. The $1.3 billion debt package was arranged by a syndicate that includes Pharmakon Advisors, a specialist lender that structures revenue interest financings secured by pharmaceutical product cash flows. The involvement of Mintz's Royalty & Revenue Interest Financing Transactions Group (led by Richard Gervase, who chairs the practice) confirms that the financing is structured, at least in part, as revenue interest debt---where repayment is tied to the commercial performance of the underlying pharmaceutical portfolio rather than traditional corporate credit metrics. This structure is increasingly common for specialty pharma platform companies with predictable, diversified commercial revenue streams.
Private equity-backed pharma platform building. B-FLEXION Life Sciences' strategy—acquiring Paratek in 2023, building it into a multi-asset platform through successive acquisitions, and financing growth through revenue-linked debt—mirrors the playbook of several PE-backed specialty pharma consolidators (including Endo, Bausch, and more recently, Harrow Health and Assertio). The $1 billion revenue scale and diversified portfolio across three therapeutic areas (bone health, infectious disease, ENT) provide the cash flow predictability that revenue interest lenders require.
Scale of the lending syndicate. The participation of five major credit investors (Blackstone, Sixth Street, Oaktree, Silver Point, Pharmakon) alongside BioPharma Credit in a single pharma financing reflects deep institutional appetite for pharmaceutical revenue-linked debt. For companies seeking non-dilutive capital structures---including royalty monetization and revenue interest financings---the Paratek/Radius syndicate demonstrates that large-scale capital is available for commercial-stage pharmaceutical assets with diversified revenue.
Alto Neuroscience: $120 Million PIPE
On March 16, 2026, Alto Neuroscience (NYSE: ANRO) announced a private investment in public equity (PIPE) for gross proceeds of approximately $120 million, making it the third-largest equity financing event of the W12 window behind the CytomX Therapeutics $250 million public offering and the CRISPR Therapeutics $600 million convertible note.
Mechanism and Clinical Context
Alto's lead program, ALTO-207, is a fixed-dose combination of pramipexole (a dopamine D3-preferring D3/D2 agonist with demonstrated antidepressant effects) and ondansetron (a 5-HT3 antagonist), designed for the treatment of treatment-resistant depression (TRD). The combination logic is pharmacological: ondansetron mitigates the dose-limiting nausea and gastrointestinal side effects of pramipexole, enabling rapid titration to therapeutically effective dopaminergic doses. Alto's broader Precision Psychiatry Platform uses EEG-derived brain biomarkers, neurocognitive assessments, and wearable device data to match patients to drug candidates---a biomarker-driven approach that parallels the precision medicine paradigms emerging in oncology and, as noted elsewhere in this term sheet, in sepsis (Sobi's EMBRACE IFNγ endotyping) and Alzheimer's (Roche's ApoE4 diagnostic).
Alto plans to initiate a Phase 2b study in H1 2026 and a Phase 3 trial in early 2027, with a potential NDA submission to follow. Pro forma for the PIPE, the company estimates cash and cash equivalents of approximately $275 million as of February 28, 2026, providing runway through Phase 3 completion. A U.S. patent (No. 12,521,374) covering methods of treating depression with ALTO-207 was issued in January 2026.
Deal Structure
| Term | Detail |
|---|---|
| Issuer | Alto Neuroscience, Inc. (NYSE: ANRO) |
| Instrument | Private investment in public equity (PIPE) |
| Gross proceeds | $120 million |
| Common shares | 2,900,000 shares at $20.00 per share |
| Pre-funded warrants | 3,100,000 warrants at $19.9999 per warrant; exercise price $0.0001; immediately exercisable; no expiration |
| Lead investor | Commodore Capital |
| Participating investors | Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and a large undisclosed biotech-dedicated investor |
| Placement agents | Jefferies (lead), BofA Securities, TD Cowen, Stifel, William Blair, Baird |
| Issuer counsel | Cooley LLP |
| Placement agent counsel | Latham & Watkins LLP |
| Expected close | March 17, 2026 |
| Use of proceeds | Phase 3 development of ALTO-207 in TRD through potential NDA submission; working capital |
| Pro forma cash | ~$275 million (as of February 28, 2026) |
Strategic and Deal Landscape Implications
The Alto PIPE is notable for several reasons beyond its size. The six-bank placement agent syndicate (Jefferies, BofA, TD Cowen, Stifel, William Blair, Baird) is unusually large for a clinical-stage biotech PIPE and signals strong institutional demand. The investor roster—mixing dedicated healthcare funds (Perceptive, Venrock Healthcare, Vestal Point) with multi-strategy capital (Commodore, Driehaus)—reflects broad conviction in the precision psychiatry thesis. Alto was simultaneously presenting at the Stifel 2026 Virtual CNS Forum (March 17-18), and the PIPE's timing alongside the conference underscores the "data-to-deal pipeline is shortening" theme noted in this term sheet's introduction.
The TRD market represents a significant commercial opportunity: approximately 30% of patients with major depressive disorder (roughly 100 million people globally) fail to respond to two or more adequate antidepressant trials. The current standard of care---Spravato (esketamine, Johnson & Johnson) and augmentation strategies---leaves substantial unmet need. No external licensing or royalty arrangements have been disclosed for ALTO-207; Alto retains full global rights.
Ovid Therapeutics: $60 Million PIPE
On March 18, 2026, Ovid Therapeutics (Nasdaq: OVID) announced a private investment in public equity (PIPE) for gross proceeds of $60 million, concurrent with the release of favorable Phase 1 safety and tolerability data for OV329 and announcement of indication expansion into tuberous sclerosis complex (TSC) seizures and infantile spasms.
Mechanism and Clinical Context
OV329 is a next-generation GABA-aminotransferase (GABA-AT) inhibitor designed to address treatment-resistant focal onset seizures and developmental and epileptic encephalopathies. Unlike vigabatrin (Sabril), the first-generation GABA-AT inhibitor with well-documented ophthalmic safety risks (progressive visual field defects), OV329 is engineered for an improved benefit-risk profile. Favorable topline safety and tolerability data from the 5 mg and 7 mg dose cohorts, including no ophthalmic safety signals, supported the decision to expand development into TSC and infantile spasms---two rare, severe pediatric epilepsies with significant unmet need.
Ovid also received regulatory clearance in Australia for OV4071, described as the first-ever oral KCC2 direct activator, being developed initially for psychosis associated with Parkinson's disease and Lewy body dementia. A Phase 1 study is planned for Q2 2026, followed by a ketamine challenge study later in 2026. A dedicated KCC2 R&D Day is scheduled for April 14, 2026.
Deal Structure
| Term | Detail |
|---|---|
| Issuer | Ovid Therapeutics Inc. (Nasdaq: OVID) |
| Instrument | Private investment in public equity (PIPE) |
| Gross proceeds | $60 million (before placement agent fees and offering expenses) |
| Common shares | 19,154,321 shares at $2.01 per share |
| Pre-funded warrants | 10,701,710 warrants at $2.009 per warrant; exercise price $0.001; immediately exercisable |
| Lead investor | Point72 |
| Participating investors | Adage Capital Management, ADAR1 Capital Management, Affinity Asset Advisors, Ally Bridge Group, Balyasny Asset Management, Coastlands Capital, Eventide Asset Management, Janus Henderson Investors, RA Capital Management |
| Lead placement agent | Leerink Partners |
| Co-placement agents | Oppenheimer & Co., LifeSci Capital |
| Legal counsel | Not disclosed in press release |
| Expected close | March 19, 2026 |
| Use of proceeds | OV329 development in TSC seizures and infantile spasms; general R&D |
| Year-end 2025 cash | $90.4 million (cash, cash equivalents, and marketable securities) |
| Pro forma runway | Into H2 2028 (per management guidance) |
Strategic Implications
The Ovid PIPE reinforces the W12 CNS financing theme alongside the Alto PIPE and the Acumen Pharmaceuticals $35.75 million private placement. The investor syndicate is deep---nine named institutional funds alongside Point72 as lead---and overlaps meaningfully with the Alto investor base (both include healthcare-focused multi-strategy funds), suggesting a coordinated institutional rotation into clinical-stage CNS assets during the Stifel CNS Forum window. The concurrent indication expansion into TSC and infantile spasms creates a potential orphan drug pathway that could accelerate regulatory timelines and enhance commercial optionality. Ovid retains full global rights to both OV329 and OV4071; no external licensing or royalty arrangements have been disclosed.
Unnatural Products: $45 Million Series B
On March 16, 2026, Unnatural Products (UNP) announced the closing of a $45 million Series B financing to advance its macrocyclic peptide therapeutics platform, bringing total equity raised since its 2019 seed round to approximately $83 million.
Platform and Pipeline
Unnatural Products has developed an integrated discovery platform combining computational design, automated chemistry, and high-throughput biological testing to engineer synthetic macrocyclic peptides at scale. Macrocyclic peptides occupy a mechanistic middle ground between small molecules and biologics: they enable highly selective binding (biologic-like) while retaining potential cell permeability and oral delivery (small molecule-like), making them suitable for intracellular targets that have historically been inaccessible to both drug modalities. The company is advancing a proprietary pipeline in cardiometabolic, inflammatory, and immunological diseases, with lead programs moving toward IND-enabling studies.
Deal Structure
| Term | Detail |
|---|---|
| Company | Unnatural Products, Inc. (Santa Cruz, CA; private) |
| Round | Series B |
| Gross proceeds | $45 million |
| Lead investor | The Venture Collective (TVC) |
| Participating investors | argenx, Droia Ventures; existing investors Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures |
| Legal counsel | Latham & Watkins LLP advised on the Series B (per published deal note) |
| Use of proceeds | Platform development; advancing lead programs toward IND-enabling studies and clinical entry |
| Total equity raised | ~$83 million (cumulative since 2019 seed) |
Licensing and Royalty Landscape
UNP's platform has attracted significant pharma licensing interest. The company's disclosed collaborations create a layered royalty and milestone potential:
| Partner | Deal | Economics |
|---|---|---|
| Novartis | Licensing agreement for macrocyclic peptide therapeutics targeting historically undruggable cardiovascular targets (announced February 2026) | Up to $100 million upfront and pre-IND milestones; up to $1.7 billion total potential development, regulatory, and commercial milestones; tiered royalties from mid-single digits to low double-digits (~4-12%) on annual net sales |
| Merck | Platform collaboration | Terms not publicly disclosed; Merck GHIF also participated in Series B |
| BridgeBio | Platform collaboration | Terms not publicly disclosed |
| argenx | Platform collaboration | Terms not publicly disclosed; argenx also participated as Series B investor |
Across its disclosed partnerships with Novartis, argenx, and Merck, UNP has accumulated over $3.5 billion in potential milestone payments, making it one of the most heavily partnered platform-stage companies at this financing scale. The Novartis collaboration alone—with its $100 million upfront/pre-IND tranche and $1.7 billion milestone tail—would generate significant royalty income if any resulting products reach commercialization. For royalty investors, the UNP platform is worth monitoring as a future royalty stream source: macrocyclic peptides targeting cardiovascular and metabolic diseases could yield large-market commercial products with royalty economics embedded in the Novartis and other licensing agreements. The participation of both argenx and Merck GHIF as both licensing partners and equity investors creates a dual financial interest structure analogous to the DaVita/U.S. Renal Care investor-channel alignment in the R1 Therapeutics deal.
Acumen Pharmaceuticals: $35.75 Million Private Placement
Acumen Pharmaceuticals (NASDAQ: ABOS) closed a private placement of approximately 10.8 million shares at $3.30 per share, raising $35.75 million (lead investor: RA Capital; also ADAR1 Capital, Sands Capital) to fund development of amyloid-beta oligomer-targeting therapies for Alzheimer's disease. The company's Enhanced Brain Delivery (EBD) platform has demonstrated approximately 40-fold higher brain exposure in non-human primates versus conventional antibodies---a potentially transformative pharmacokinetic advantage for central nervous system targets.
Longeveron: $30 Million Private Placement
Longeveron (NASDAQ: LGVN) raised up to $30 million ($15 million at initial close, plus $15 million contingent on milestone achievement) from Coastlands Capital, Janus Henderson, Logos Capital, and Kalehua Capital (placement agent: H.C. Wainwright & Co.). The proceeds will fund Longeveron's Phase 2b ELPIS II trial of laromestrocel, an allogeneic mesenchymal stem cell therapy, in Hypoplastic Left Heart Syndrome. Cash runway extends to Q4 2026, past an expected Q3 2026 topline readout.
Serina Therapeutics: Up to $30 Million Private Placement
On March 18, 2026, Serina Therapeutics (NYSE American: SER) announced a milestone-gated private placement for up to $30 million in gross proceeds, structured as a $15 million first tranche closing immediately and a second tranche of up to $15 million available through April 30, 2026, subject to milestone achievement. The offering includes common shares, pre-funded warrants, and accompanying warrants. Board member Greg Bailey led the investment.
Serina is developing SER-252, a polymer-conjugated levodopa designed to provide sustained, non-pulsatile dopamine delivery for the treatment of motor fluctuations in advanced Parkinson's disease. The proceeds will fund a registrational clinical trial of SER-252. The financing adds to the W12 CNS capital deployment cluster alongside Alto ($120 million), Ovid ($60 million), Acumen ($35.75 million), and Longeveron ($30 million), and connects thematically to the AD/PD 2026 Parkinson's data from Aspen Neuroscience (ASPIRO 12-month cell therapy), Herantis Pharma (HER-096 CDNF-mimetic), and IRLAB Therapeutics (pirepemat falls data). No licensing, royalty, or partnership arrangements have been disclosed.
Reviva Pharmaceuticals: ~$10 Million Public Offering
On March 18, 2026, Reviva Pharmaceuticals (Nasdaq: RVPH) priced a public offering with institutional investors for approximately $10 million in gross proceeds. The offering comprised common shares, Series G warrants (5-year term, $1.50 strike), and Series H warrants (12-month term, $1.50 strike) at a combined offering price of $1.50. A.G.P./Alliance Global Partners served as sole placement agent. The offering was conducted under an existing shelf registration (S-3).
Reviva's lead asset is brilaroxazine, an atypical antipsychotic in Phase 3 development for schizophrenia, with additional Phase 2 programs in major depressive disorder and Alzheimer's disease-related psychosis. The financing further extends the W12 CNS financing theme, bringing total CNS-focused equity raised during the week above $285 million across six transactions (Alto, Ovid, Acumen, Longeveron, Serina, Reviva).
Mestag Therapeutics: $40 Million Financing to Enter the Clinic
On March 17, 2026, Mestag Therapeutics announced the closing of a $40 million financing, bringing total funds committed to date above $95 million. The round was supported by the full existing investor syndicate: SV Health Investors (which founded the company), Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (Google Ventures), and Northpond Ventures.
Deal Context and Use of Proceeds
The financing is explicitly tied to clinical entry: proceeds will fund the Phase 1 STARLYS clinical trial of MST-0312 in solid tumor patients, anticipated to start mid-2026, alongside platform and pipeline activities in inflammatory diseases. Concurrent with the financing close, Mestag appointed Lindsey Rolfe (formerly CMO at Clovis Oncology, where she led the U.S. and EU marketing approvals for Rubraca) as Chief Medical Officer and Pascal Merchiers (formerly CSO at Aboleris and Oncurious; previously Tusk Therapeutics, acquired by Roche in 2018 for $759 million) as Chief Development Officer---a leadership expansion that signals imminent IND-enabling execution.
Mechanism and Scientific Rationale
MST-0312 is a first-in-class FAP-targeted bispecific antibody that agonizes the lymphotoxin-beta receptor (LTBR) on cancer-associated fibroblasts (CAFs) to induce the formation of tertiary lymphoid structures (TLS) and high endothelial venules (HEV) within solid tumors. The therapeutic logic is grounded in a growing clinical evidence base showing that the presence of TLS in solid tumors correlates with improved patient survival and enhanced response to immunotherapy---including in tumor types that are typically resistant to checkpoint inhibitors. By using FAP targeting to localize LTBR agonism specifically to the tumor stroma, MST-0312 aims to create organized immune hubs within the tumor microenvironment, facilitating local antigen presentation and lymphocyte activation.
Preclinical data presented at the Cancer Immunotherapy Keystone Symposia (March 15-18, Quebec City) showed that MST-0312 monotherapy induces strong, dose-dependent anti-tumor responses in mouse models, including in low-antigen tumors that are typically resistant to immunotherapy---a critical differentiator if it translates clinically.
Competitive Landscape and Strategic Position
Mestag's approach targets the tumor stroma rather than the tumor cell or the systemic immune compartment, placing it in a mechanistically distinct category from checkpoint inhibitors, T-cell engagers, and ADCs. The company's broader fibroblast-immune platform includes M402, an agonist antibody targeting a stromal inhibitory receptor for inflammatory diseases (RA, IBD, lupus), and the RAFT target discovery platform, which is the subject of a license and research collaboration with MSD (Merck) announced in 2024. The founding scientific team includes Michael Brenner (Brigham & Women's/Harvard), Chris Buckley (Oxford), and David Tuveson (Cold Spring Harbor/AACR President), providing deep academic roots in fibroblast biology and the tumor microenvironment.
Mestag Partnership Landscape: MSD and J&J Licensing Economics
Mestag's RAFT platform has attracted two major pharma licensing deals. The October 2024 license and research collaboration with MSD (Merck) grants MSD options to obtain exclusive licenses to develop and commercialize therapeutics against a prespecified number of targets identified using the RAFT platform in inflammatory diseases including IBD, rheumatoid arthritis, and kidney disease. Mestag receives an upfront payment and access fees (specific amounts undisclosed), with eligibility for option fees and downstream payments potentially totaling $1.9 billion in aggregate---encompassing upfront, access fees, per-target option fees, development milestones, regulatory milestones, and commercial milestones. MSD assumes all discovery, development, and commercialization responsibility for licensed targets, and is eligible for royalties on any commercialized products (rates undisclosed). The $1.9 billion headline represents the total biobucks potential across all optioned targets; per-target economics and royalty rates were not disclosed, and as a private UK biotech with no SEC filing obligations, Mestag has no requirement to itemize deal components. Separately, in December 2024, Johnson & Johnson exclusively licensed a novel undisclosed target identified via the RAFT platform under a multi-year target discovery, option, and license agreement with Janssen Biotech originally established in May 2021. The original 2021 agreement gave Janssen options to exclusive licenses on up to two targets, with compensation including option fees, milestone payments, and royalties—all at undisclosed amounts and rates. J&J (via JJDC) also participated as an equity investor in Mestag's $45 million seed extension in August 2021, creating a dual financial interest structure. The December 2024 target exercise triggers eligibility for "future downstream payments," but no headline deal value was announced---in contrast to the $1.9 billion MSD collaboration. These two platform-level deals validate Mestag's target discovery capabilities and provide non-dilutive funding alongside the $40 million equity round.
The Mestag financing, alongside the VST BIO Series A ($45 million cumulative via philanthropic capital) and R1 Therapeutics' oversubscribed $77.5 million Series A launch, adds to the W12 capital markets tally and reinforces a pattern seen across recent weeks: clinical-stage companies with differentiated mechanisms and blue-chip syndicates continue to attract capital despite a selective funding environment. The R1 deal is particularly instructive for its vertically integrated investor-channel partner structure, where dialysis providers DaVita and U.S. Renal Care are simultaneously funding development and controlling patient access.
VST BIO Corporation: $45 Million Series A Led by Coefficient Giving
On March 17, 2026, VST BIO Corporation announced the closing of its Series A financing, led by Coefficient Giving, a philanthropic funder that has directed more than $4 billion in grants since 2014 across global health, science R&D, and other cause areas. Coefficient Giving funding partners have invested a cumulative $45 million in VST BIO since the company's inception in 2020.
Lead Program: VB-001
VB-001 is a first-in-class humanized monoclonal antibody targeting Syndecan-2 (SDC2), designed to address vascular leak and inflammation in acute ischemic stroke. Unlike existing stroke therapeutics, which focus on clot removal (tPA, mechanical thrombectomy) during the hyperacute window, VB-001 targets the secondary vascular permeability and inflammatory cascades that drive cerebral edema and tissue damage in the hours and days following the initial ischemic event. In preclinical non-human primate stroke models, VB-001 reduced vascular permeability and infarct size by 50-60%. The antibody has also demonstrated efficacy in rodent models of septic shock (reduced mortality) and cytokine storm (reduced cytokine release in response to LPS), suggesting a broader vascular inflammation platform.
The Series A proceeds will fund VB-001's advance into first-in-human studies in 2026, platform expansion, and core development capabilities.
Governance and Strategic Additions
Concurrent with the financing, VST BIO appointed William Sessa to its Board of Directors. Sessa most recently served as SVP and CSO for Internal Medicine at Pfizer (until mid-2025), where he led early-stage discovery through Phase 2b programs in metabolic-driven cardio-renal syndrome. He is also Alfred Gilman Emeritus Professor in the Department of Pharmacology at Yale School of Medicine. VST BIO was co-founded by Michael Simons, a leading vascular biologist at Yale.
Financing Structure and Strategic Context
The VST BIO financing is unusual in several respects. Coefficient Giving operates as a philanthropic advisor rather than a traditional venture capital or institutional investor, partnering with major donors on high-impact giving in global health and science R&D. The $45 million cumulative investment reflects a philanthropic thesis that stroke therapeutics represent an underinvested area with outsized global health impact---acute ischemic stroke is the second leading cause of death worldwide and a leading cause of adult disability, yet the therapeutic armamentarium has seen minimal innovation beyond the acute reperfusion window.
For dealmakers, VST BIO's progression to first-in-human studies creates a potential future licensing or partnering opportunity in a large, underserved indication. The vascular leak platform's applicability beyond stroke (sepsis, cytokine release syndrome, potentially ARIA management in the context of anti-amyloid therapies) expands the strategic optionality for downstream deals.
Salspera: $85-91 Million IPO Filing Active
Salspera Inc. (proposed NASDAQ: TKVA) maintained an active $85-91 million IPO filing (sole book-runner: Kingswood Capital Partners; 5.7 million shares targeted at $14-$16 per share) during the window for its Phase 3 Salmonella-based bacterial immunotherapy program. The lead asset, saltikva, is an attenuated Salmonella typhimurium strain engineered to selectively colonize solid tumors and stimulate immune-mediated tumor destruction. Phase 2 data in pancreatic cancer showed a 70% partial response rate---a striking result in a disease with historically poor immunotherapy outcomes. If successful, Salspera would represent one of the first pure-play live bacterial immunotherapy companies on a U.S. exchange.
SAB Biotherapeutics: $85 Million Public Offering
On March 18, 2026, SAB Biotherapeutics (NASDAQ: SABS) priced an underwritten public offering of approximately 19.3 million shares at $3.85 per share plus pre-funded warrants, generating approximately $85 million in gross proceeds. Joint book-runners were Jefferies, UBS, Citigroup, and Barclays, with Chardan as lead manager. Proceeds will fund the Phase 2b SAFEGUARD trial of SAB-142, a fully human polyclonal anti-thymocyte immunoglobulin produced using SAB's proprietary DiversitAb platform (genetically engineered cattle that produce human antibodies), in Type 1 diabetes.
TG Therapeutics / Blue Owl Capital: $750 Million Senior Secured Credit Facility
On March 19, 2026, TG Therapeutics (NASDAQ: TGTX) announced a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital (NYSE: OWL), one of the most active non-dilutive lenders in the pharmaceutical sector.
Deal Structure
| Term | Detail |
|---|---|
| Borrower | TG Therapeutics, Inc. (NASDAQ: TGTX) |
| Lender | Funds managed by Blue Owl Capital (NYSE: OWL) |
| New facility size | $750 million senior secured term loan |
| Tenor | Five years |
| Incremental option | Up to $250 million additional capital (mutual discretion), for total facility size of up to $1 billion |
| Prior facility repaid | $250 million senior secured credit facility (Blue Owl, August 2024) |
| Net new capital raised | $500 million |
| Share repurchase expansion | Board authorized increase from $100 million to $300 million |
| Shares repurchased to date | ~$38 million at average price of $28.98/share (as of March 18, 2026) |
| Use of proceeds | Share repurchases, business development, BRIUMVI growth investment, pipeline advancement |
| Lender counsel | Cooley LLP (Partners Michael Tollini and Addison Pierce; patent: Jon Cousin; life sciences: Geoffrey Spolyar; tax: Xander Lee) |
| SEC filing | Form 8-K (anticipated) |
Commercial Context and Credit Profile
TG Therapeutics is the commercial-stage company behind BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis (RMS). BRIUMVI generated $594.1 million in U.S. net product revenue for FY2025 (approximately 92% year-over-year growth) and $616.3 million in total global revenue, with commercialization expanding across Europe, the UK, Switzerland, Australia, Kuwait, and the UAE through a partnership with Neuraxpharm. The company raised full-year 2026 BRIUMVI revenue guidance, and its pipeline includes a subcutaneous ublituximab formulation (~75% enrolled into Phase 3), a consolidated Day 1/Day 15 IV dosing regimen (Phase 3 ENHANCE trial), and azer-cel, a CAR-T cell therapy in Phase 1 for autoimmune diseases including progressive MS.
The credit profile is notable: TG Therapeutics is now cash-flow positive from operations, with rapidly growing commercial revenues backing a substantial non-dilutive borrowing capacity. The $750 million facility, with its $250 million accordion feature potentially extending total capacity to $1 billion, reflects lender confidence in BRIUMVI's revenue trajectory and the durability of TG's MS franchise.
Blue Owl's Pharma Lending Franchise
The TG Therapeutics deal extends Blue Owl's increasingly visible franchise in pharmaceutical-grade non-dilutive lending. Blue Owl's recent life sciences credit portfolio includes:
| Date | Borrower | Facility Size | Context |
|---|---|---|---|
| December 2023 | XOMA Corporation | Up to $140 million | Royalty aggregation financing |
| January 2024 | BridgeBio Pharma | Up to $1.05 billion | Commercial-stage rare disease |
| August 2024 | TG Therapeutics | $250 million | Initial BRIUMVI credit facility |
| May 2025 | ITM Isotope Technologies Munich | Up to $262.5 million | Radiopharmaceutical supply chain |
| July 2025 | Madrigal Pharmaceuticals | Up to $500 million | Rezdiffra (MASH) launch financing |
| March 2026 | TG Therapeutics | $750 million (up to $1 billion) | BRIUMVI franchise expansion |
The pattern is clear: Blue Owl is building a differentiated lending book focused on commercial-stage pharmaceutical companies with validated revenue streams, offering facility sizes that were historically the province of bank syndications or public debt markets. The Cooley advisory relationship across multiple Blue Owl pharma deals (BridgeBio, TG Therapeutics, ITM, Madrigal) suggests an institutionalized legal framework for structuring these transactions.
Implications for the Non-Dilutive Financing Landscape
The TG/Blue Owl deal, combined with the $1.3 billion Blackstone-led debt financing for the Paratek-Radius Health combination earlier in W12, underscores the maturation of private credit as a primary capital source for commercial-stage pharmaceutical companies. For royalty investors and deal structurers, the relevant observation is structural: as private credit providers like Blue Owl, Blackstone, and Healthcare Royalty Partners scale their pharma lending operations, the competitive landscape for non-dilutive capital is expanding—creating both more options for borrowers and more sophisticated risk assessment frameworks that blend patent life analysis, revenue forecasting, and product lifecycle management into credit underwriting.
Zenas BioPharma / Pharmakon Advisors: $250 Million Senior Secured Debt Facility
On March 16, 2026, Zenas BioPharma (Nasdaq: ZBIO) announced, alongside its FY2025 earnings, a five-year, up to $250 million senior secured debt facility with funds managed by Pharmakon Advisors, LP---the specialist lender behind BioPharma Credit (LSE: BPCR) and a participant in the Paratek/Radius Health $1.3 billion debt syndicate also closed in W12.
Deal Structure
| Term | Detail |
|---|---|
| Borrower | Zenas BioPharma, Inc. (Nasdaq: ZBIO; Waltham, MA) |
| Lender | Funds managed by Pharmakon Advisors, LP |
| Facility size | Up to $250 million |
| Tranche structure | Five tranches: $75 million at closing; additional $175 million available through April 30, 2029 |
| Discretionary draws | $125 million of the $175 million conditional tranches at Zenas's discretion |
| Conditions | Remaining tranches subject to obexelimab IgG4-RD regulatory and commercial milestones |
| Interest rate | 3-month SOFR + 575 bps, with a 3.25% SOFR floor (effective minimum rate ~9.00%) |
| Origination fees | 2.00% on Tranche A; 2.00% on first $50M of Tranche B; 1.00% on excess; 1.00% on Tranches C-E |
| Equity component | None --- no warrants or equity kicker; deal characterized as fully non-dilutive |
| Additional contingent | $75 million from Royalty Pharma upon FDA approval of obexelimab for IgG4-RD (separate from Pharmakon facility) |
| Term | Five years |
| Borrower cash position | $360.5 million (cash, equivalents, and investments at December 31, 2025) |
| Projected runway | Into Q2 2027 without conditional tranches; into Q4 2027 with milestone-linked draws |
Clinical and Commercial Context
The facility is timed to Zenas's pre-commercial ramp for obexelimab, a bifunctional anti-CD19 monoclonal antibody that achieved the primary endpoint in the Phase 3 INDIGO registrational trial with a 56% reduction in IgG4-related disease (IgG4-RD) flare risk versus placebo. Zenas plans a BLA submission to the FDA in Q2 2026 and a MAA to the EMA in H2 2026. The broader pipeline includes orelabrutinib (BTK inhibitor) in Phase 3 for progressive multiple sclerosis, ZB021 (oral IL-17AA/AF inhibitor, Phase 1 expected Q2 2026), and ZB014 (a half-life-extended anti-CD19/FcγRIIb mAb that could offer quarterly dosing).
Strategic Implications for Non-Dilutive Lending
The Zenas/Pharmakon facility extends the W12 non-dilutive capital theme alongside the Blackstone-led Paratek/Radius $1.3 billion package, Blue Owl's $750 million TG Therapeutics facility, and the QHP/Azurity $1.1 billion continuation vehicle. Pharmakon's participation in both the Paratek/Radius syndicate and the standalone Zenas facility within a single week underscores the firm's growing role as a pre-commercial pharmaceutical lender---extending credit against BLA-stage assets with strong Phase 3 data rather than requiring established commercial revenue. Combined with the Collegium $300 million delayed-draw term loan funding the AZSTARYS acquisition and Indivior's $500 million convertible senior notes, W12 produced over $4.1 billion in private credit and convertible debt deployed to pharmaceutical companies across six distinct structures.
QHP Capital: $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals
On March 18, 2026, QHP Capital announced the closing of a $1.1 billion GP-led single-asset continuation vehicle for Azurity Pharmaceuticals, a specialty pharma platform QHP has owned since acquiring CutisPharma (Azurity's predecessor) from Ampersand Capital Partners in March 2018. The transaction, which closed on February 13, 2026, transfers Azurity from QHP's original fund into a newly formed vehicle, providing liquidity to existing limited partners while allowing QHP to retain control of the asset.
Deal Structure
| Term | Detail |
|---|---|
| Sponsor | QHP Capital (Durham, NC; formerly NovaQuest Private Equity) |
| Asset | Azurity Pharmaceuticals, Inc. (Woburn, MA; private) |
| Vehicle | Single-asset GP-led continuation vehicle |
| Enterprise value | $1.1 billion |
| Anchor investor | HarbourVest Partners ($146 billion AUM) |
| Co-investor | Pantheon Ventures ($85 billion AUM) |
| Syndicate investor + growth capital | Audax Strategic Capital (dual role: CV investor + structured growth investment with earmarked acquisition capital) |
| QHP participation | QHP's subsequent fund remains a significant investor in Azurity |
| LP options | Existing LPs could cash out or roll into the new CV; strong participation reported |
| Financial advisor | Goldman Sachs & Co. LLC |
| Placement agents | Goldman Sachs & Co. LLC and Eaton Partners (division of Stifel Nicolaus) |
| Legal advisor | Ropes & Gray, LLP |
| Closing date | February 13, 2026 (announced March 18, 2026) |
Azurity's Transformation: From 50-Person Compounder to Global Specialty Pharma
Under QHP ownership, Azurity has completed five acquisitions, transforming from a ~50-employee prescription compounding company into a global specialty pharma platform operating across 50+ countries with 50+ medicines spanning 10 dosage forms and 10 therapeutic areas:
| Acquisition | Year | Strategic Impact |
|---|---|---|
| Silvergate Pharmaceuticals | 2019 | Created the Azurity brand; pediatric/geriatric focus |
| Arbor Pharmaceuticals (from JW Asset Management / KKR) | 2021 | Added 30+ products in neuroscience, cardiovascular, institutional |
| Slayback Pharma (from KKR / Everstone Capital) | 2023 | Added complex pharmaceutical R&D capabilities |
| Covis Pharma Group | 2025 | Expanded to 50+ countries; added respiratory franchise (ALVESCO, TUDORZA) |
| Sebela Pharmaceuticals' bowel prep franchise | 2025 | Added two leading colonoscopy preparation therapies |
The current product portfolio spans cardiovascular (11 products including BiDil, EDARBI, KATERZIA, JAVADIN), CNS/cerebrovascular (10 products including ARYNTA for ADHD), oncology (GLIADEL Wafer, DANZITEN), respiratory, endocrinology, GI, and hematology. Azurity secured six FDA approvals in 2024-2025, including ARYNTA (lisdexamfetamine oral solution for ADHD), FERABRIGHT (the first iron-based MRI contrast agent for brain imaging), and JAVADIN (first ready-to-use clonidine oral solution). CEO Ronald Scarboro leads the current management team.
Strategic and Market Implications
The QHP/Azurity transaction is structurally distinct from the debt financings and royalty deals that dominate W12's capital markets activity. Continuation vehicles are a GP-led secondary market mechanism: rather than exiting the investment through a traditional sale or IPO, QHP transfers Azurity into a new fund structure, resetting the hold period and capital base while maintaining operational control. This contrasts with revenue interest or royalty financing (e.g., the Blackstone-led Paratek/Radius debt package or Blue Owl's TG Therapeutics credit facility), where capital is secured against future product revenues.
The deal reflects the maturation of the GP-led secondaries market, which reached approximately $75 billion in 2024 within a total secondaries market of $162 billion. At $1.1 billion, the Azurity CV demonstrates that continuation vehicles have migrated beyond mega-fund PE firms into the healthcare middle market, where specialist GPs like QHP can use CVs to extend ownership of high-performing platform companies. Comparable healthcare CVs include New Mountain Capital's $3.1 billion deal for Real Chemistry (April 2025).
For the pharmaceutical deal landscape, QHP's strategy—acquiring a small specialty pharma company, building it into a multi-product, multi-geography platform through serial M&A, and then using a continuation vehicle to maintain control while providing investor liquidity—represents an alternative to the B-FLEXION/Paratek model (PE-backed platform consolidation financed by revenue-linked debt) and the Blue Owl/TG model (credit facilities against commercial-stage revenues). The inclusion of Audax Strategic Capital's structured growth investment with earmarked acquisition capital signals that Azurity's M&A pipeline remains active, potentially positioning the company for further portfolio expansion in specialty pharma.
iDEL Therapeutics: EUR 9 Million Seed Financing
On March 17, 2026, iDEL Therapeutics, a Dortmund, Germany-based oncology company, closed a EUR 9 million (~$10.4 million) seed round led by BiomedVC with participation from NRW.Venture, Grunderfonds Ruhr, and KHAN Technology Transfer Fund II. The company's platform delivers cancer drugs directly into the cytosol of tumor cells, bypassing endosomal trapping---a common mechanism of resistance for antibody-drug conjugates and targeted therapies.
Crossbow Therapeutics: $77 Million Series B
On March 18, 2026, Crossbow Therapeutics announced the closing of a $77 million Series B financing to advance its TCR-mimetic antibody platform for cancer treatment.
Deal Structure
| Term | Detail |
|---|---|
| Company | Crossbow Therapeutics (Cambridge, MA; private) |
| Round | Series B |
| Gross proceeds | $77 million |
| Co-lead investors | Taiho Ventures, Arkin Bio Capital (new) |
| New investors | Sixty Degree Capital, Hamilton Square Partners, LifeLink Ventures, Libbs Ventures, Blood Cancer United Therapy Acceleration Program |
| Existing investors | MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly, Mirae Asset |
| Use of proceeds | Complete Phase 1 CROSSCHECK-001 trial of CBX-250 (first-in-class TCR-mimetic T-cell engager for myeloid malignancies); advance CBX-663 (TERT-targeted TCE) toward IND filing (Q3 2026) |
Strategic Context
Crossbow's TCR-mimetic approach enables T-cell engagement against intracellular tumor targets---a mechanistic differentiator from conventional T-cell engagers that are limited to surface antigens. The participation of Taiho Ventures (Otsuka pharmaceutical group) alongside Pfizer Ventures and Eli Lilly signals multi-pharma validation of the platform's therapeutic potential. Combined with CytomX's $250 million public offering and Excalipoint's $68.7 million seed launch, the Crossbow Series B makes W12 one of the most active weeks for T-cell engager financing in 2026.
ProLynx: $70 Million Series A
On approximately March 19, 2026, ProLynx (Emeryville, CA) closed a $70 million Series A led by 5AM Ventures, OrbiMed, and Monograph Capital to develop longer-acting incretin and non-incretin therapies for obesity targeting monthly dosing regimens. The round adds to the W12 obesity financing theme alongside Structure Therapeutics' positive aleniglipron Phase 2 data and Congruence Therapeutics' first-patient dosing of CGX-926 (MC4R corrector), reinforcing the sector's continued capital formation momentum.
Excalipoint Therapeutics: $68.7 Million Seed (Company Launch)
On March 18, 2026, Excalipoint Therapeutics launched with a $68.7 million seed financing—one of the largest seed rounds in Chinese biotech history—structured as a $41 million initial seed (August 2025, co-led by HSG/Sequoia China, Apricot Capital, Yuanbio) plus a $27.7 million extension (co-led by MPCi/Matrix Partners China and Centurium Capital, with Lilly Asia Ventures and Eisai Innovation). Based in Shanghai, Excalipoint operates six T-cell engager programs across three proprietary platforms; lead candidate EXP011 (CTM012) is in Phase 1/2 for DLL3-positive solid tumors. The programs were licensed from Lepu Biopharma for $10 million upfront. The participation of both Lilly and Eisai venture arms in a Chinese TCE platform underscores the global race for next-generation T-cell engager technology.
Outlook Therapeutics: $18.4 Million Non-Convertible Note Financing
On March 16, 2026, Outlook Therapeutics (Nasdaq: OTLK) announced a new $18.4 million non-convertible, unsecured note financing and a concurrent amendment to its existing convertible note.
Deal Structure
| Term | Detail |
|---|---|
| Borrower | Outlook Therapeutics, Inc. (Nasdaq: OTLK) |
| New note lender | Atlas Sciences, LLC |
| New note principal | $18.4 million (non-convertible, unsecured) |
| Original issue discount | $1.36 million |
| Net proceeds | $17 million |
| Interest rate | Prime Rate + 3% (minimum floor: 9.5% per annum) |
| Maturity | June 16, 2027 (15 months from closing) |
| Redemption rights | Beginning on 6-month anniversary, lender may redeem up to $3 million per calendar quarter |
| Exit fee | 7.5% on all cash payments (prepayments, redemptions, or maturity repayment) |
| Existing note amendment | Avondale Capital, LLC convertible note maturity extended to December 31, 2026; no other term changes; lender confirmed no default |
| Use of proceeds | Partial paydown of existing Avondale convertible note, reducing balance to approximately $10.8 million of principal and interest |
Context
Outlook Therapeutics is focused on commercializing ONS-5010/LYTENAVA (bevacizumab gamma), the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA marketing authorization for wet AMD. The company has commenced commercial launch in Germany, Austria, and the UK. In the U.S., ONS-5010 remains investigational following a Type A FDA meeting in early March 2026. The $18.4 million note represents a bridge financing that restructures existing debt rather than funding new development---the proceeds are used to pay down the Avondale note, not to fund clinical programs. No licensing, royalty, or partnership arrangements are implicated by this financing.
Celiac Disease Foundation: $15 Million Venture Philanthropy Impact Fund Launch
On March 18, 2026, the Celiac Disease Foundation announced the launch of the Celiac Disease Foundation Impact Fund, a venture philanthropy fund with a phase one fundraising target of $15 million. Managed in partnership with Triple G Ventures, the Impact Fund will deploy disciplined investment capital in scalable innovations across early detection, prevention, education, awareness, and breakthrough therapies for celiac disease—including enzyme therapies, immune tolerance approaches, and gene- and cell-based treatments.
The Impact Fund is structured as a recycling vehicle: as investments generate returns, gains are reinvested to support future innovation, creating a sustainable cycle that multiplies philanthropic capital over time. An independent investment committee and advisory network will guide portfolio decisions.
While the Impact Fund is not a pharmaceutical transaction in the traditional sense---the $15 million represents a fundraising goal, not capital deployed---it merits inclusion in the W12 term sheet for two reasons. First, it extends the venture philanthropy model that appeared earlier this week with VST BIO's $45 million Coefficient Giving-led Series A, reinforcing a pattern of mission-driven capital flowing into underserved therapeutic areas through structures that blend philanthropic intent with venture discipline. Second, celiac disease represents a genuinely underfunded autoimmune indication: approximately 3 million Americans are affected, yet 70-80% remain undiagnosed, and the disease has no approved pharmacological treatment beyond dietary gluten avoidance. The celiac therapeutics pipeline---including companies such as Takeda (TAK-101, now at Anokion/Provention Bio), 9 Meters Biopharma (larazotide), and ImmunogenX (latiglutenase)---has attracted sporadic pharma interest but lacks the sustained investment infrastructure that the Impact Fund aims to build.
For dealmakers, the Celiac Disease Foundation Impact Fund signals a potential source of catalytic early-stage capital in a disease area where the therapeutic development pipeline has historically been constrained more by funding than by science. Companies emerging from the Impact Fund's portfolio could become future licensing or acquisition candidates as celiac disease moves from dietary management toward pharmacological intervention.
Congruence Therapeutics: $39.5 Million Financing and Phase 1/1b First Dosing
On March 19, 2026, Congruence Therapeutics announced the closing of a US $39.5 million financing round co-led by new investor Dimension and existing investor OrbiMed, with participation from Amplitude Ventures, FSTQ, Lumira, Investissement Québec, BDC Capital's Thrive Venture Fund, Driehaus, and Silver Arc. Simultaneously, Congruence announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-molecule MC4R corrector being developed for the treatment of genetic obesity caused by mutations in the melanocortin-4 receptor (MC4R). This follows a $32 million round closed in September 2025 that funded the CTA filing and trial preparation.
Mechanism and Competitive Context
CGX-926 represents a mechanistically differentiated approach to MC4R-related obesity. Where Rhythm Pharmaceuticals' Imcivree (setmelanotide) is an MC4R agonist---attempting to activate the receptor downstream of the mutation---Congruence's approach is a corrector that rescues the misfolded MC4R protein itself, enabling the receptor to reach the cell surface and function normally. Missense mutations in MC4R are the most common monogenic cause of obesity, leading to early-onset hyperphagia and severe weight gain. The MC4R corrector mechanism is analogous to Vertex's CFTR corrector approach in cystic fibrosis: rather than compensating for the absent receptor signal, CGX-926 restores the native protein to functional status.
The timing is notable. Rhythm's Imcivree failed all four substudies of the Phase 3 EMANATE trial in rare MC4R pathway diseases earlier in W12---a result that demonstrated the limitations of agonist approaches in heterogeneous MC4R-mutant populations. Congruence's corrector mechanism is orthogonal: by restoring receptor surface expression, it could theoretically benefit the subset of MC4R-deficient patients whose mutations cause misfolding (estimated at approximately 80% of pathogenic MC4R missense mutations) rather than loss-of-function through other mechanisms. The Rhythm EMANATE failure and Congruence's first dosing in the same week frame a pivot point in the MC4R therapeutic landscape.
Trial Design and Development Timeline
The Phase 1/1b study is designed to evaluate safety, tolerability, and pharmacokinetics of CGX-926 in healthy volunteers, with a Phase 1b efficacy cohort enrolling individuals with MC4R-deficient obesity at the University of Cambridge under Professor Sadaf Farooqi, the world's leading clinician scientist in the genetic causes of obesity and the principal investigator on multiple prior setmelanotide trials. Congruence has engaged Quotient Sciences to execute the trial using their Translational Pharmaceutics platform. Data are expected in the first half of 2027. The proceeds from the $39.5 million financing will also fund IND-enabling work for two additional programs targeting GBA1-driven Parkinson's disease and alpha-1 antitrypsin (A1AT) deficiency, with CTA/IND filings targeted for early 2027.
Platform and Partnering Relevance
Congruence's proprietary Revenir computational platform---which models the conformational dynamics of proteins across functional states to identify cryptic and allosteric binding sites where small molecule correctors can stabilize native protein folds---underpins the entire pipeline. The company has an existing multi-target research collaboration with Ono Pharmaceuticals spanning oncology, neurology, and immunology, as well as a separate collaboration with an undisclosed global pharmaceutical company on a metabolic target. The Ono relationship encompasses two agreements: a December 2024 oncology collaboration and a March 2026 expansion into neurology and immunology. Under both agreements, Ono receives exclusive worldwide option rights to develop and commercialize corrector molecules identified using Congruence's Revenir platform, with Ono reimbursing all of Congruence's research and development expenses and paying undisclosed upfront fees, milestone payments at discovery, development, approval, and commercial milestones, and tiered royalties on annual net sales of any commercialized products. While specific dollar amounts and royalty percentages remain undisclosed across both agreements, the two-deal structure with a major Japanese pharma company validates the Revenir platform's utility across multiple therapeutic areas and creates a layered milestone and royalty potential that could become material if any Ono-optioned programs reach commercialization. CEO Dr. Clarissa Desjardins previously founded Clementia Pharmaceuticals, sold to Ipsen for $1.31 billion in 2019—a track record that lends credibility to both the science and the eventual exit strategy.
For dealmakers and royalty investors, Congruence occupies an interesting intersection: a platform company with multiple Big Pharma collaborations (Ono, undisclosed partner), a lead program entering clinical development in a high-value metabolic indication where the competitive field just narrowed (Rhythm EMANATE failure), and a founding team with a demonstrated billion-dollar exit. The Ono and undisclosed pharma collaborations could generate future royalty and milestone streams if partnered products advance---making Congruence a watchlist addition for the royalty community.
Azitra: $10.5 Million Private Placement (up to $31.4 Million with Warrants)
On March 19, 2026, Azitra, Inc. (NYSE American: AZTR) announced the pricing of a private placement financing for gross proceeds of up to approximately $31.4 million, including initial gross proceeds of approximately $10.5 million and up to an additional $20.9 million upon potential cash exercise of accompanying warrants. The transaction is expected to close on or about March 20, 2026. Participating investors include Stonepine Capital, Nantahala Capital, and other institutional healthcare-focused funds, along with certain company insiders.
Azitra is a clinical-stage biopharmaceutical company developing live biotherapeutic products for precision dermatology. The lead program, ATR-12, uses an engineered strain of Staphylococcus epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options that may be fatal in infancy. ATR-12 has received Fast Track designation from the FDA. The company's second clinical program, ATR-04, targets EGFRi-associated rash using another engineered S. epidermidis strain, addressing a dermatologic toxicity that affects approximately 150,000 patients annually in the United States who are undergoing EGFR inhibitor cancer therapy.
The financing is a micro-cap survival round for a company facing NYSE American delisting risk due to stockholders' equity shortfalls. While Azitra's live biotherapeutic platform is scientifically novel, the company has no disclosed licensing, royalty, or partnership structures, and the deal carries no direct implications for the royalty or deal-structuring community. The financing is included for completeness as a W12 equity transaction.
Additional W12 Deals and Transactions
Several additional transactions were announced during the W12 window that, while smaller in scale, reflect broader trends in the life sciences deal landscape:
Brenig Therapeutics: Phase 1 Data Presented at AD/PD 2026 (March 17). Brenig Therapeutics presented Phase 1 clinical data for BT-267, a LRRK2 inhibitor for Parkinson's disease, in an oral presentation at AD/PD 2026, alongside updates on BT-409, its NLRP3 inhibitor program for neuroinflammatory conditions. Brenig's $65 million Series A was closed in July 2024 (led by NEA with BioGeneration Ventures, OrbiMed, and Torrey Pines); the W12 event is a clinical data milestone rather than a new financing.
Whitehawk Therapeutics / WuXi Biologics: AACR 2026 Abstracts (March 17). Whitehawk Therapeutics (formerly Aadi Bioscience) announced three preclinical abstracts accepted at the AACR 2026 Annual Meeting (April 17-22) for its antibody-drug conjugate pipeline: HWK-007 (PTK7-targeting ADC), HWK-016 (MUC16-targeting ADC, selected for an oral minisymposium presentation), and HWK-206 (SEZ6-targeting ADC). The HWK-016 program was developed in collaboration with WuXi Biologics under the company's ongoing partnership for ADC discovery and manufacturing. This is consistent with the cross-border biologics partnerships described in the R1/Alebund and Sentynl/PRG S&T analyses above.
Leading Biotech Company / Portal Instruments: PRIME NEXUS Co-Development (March 17). An undisclosed leading biotech company entered into a co-development agreement with Portal Instruments for the PRIME NEXUS needle-free injection platform, targeting subcutaneous delivery of biologics including GLP-1 receptor agonists. The deal reflects the growing importance of device-drug combination products and delivery innovation as the GLP-1 market scales toward mass-market adoption. The preclinical-stage collaboration focuses on enabling subcutaneous administration pathways that could improve patient compliance and reduce healthcare system costs.
Cellipont Bioservices / BobcatBio: Manufacturing Collaboration (March 17). Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO), entered a collaboration with BobcatBio to support manufacturing of RB-1355, a Phase 1 candidate for solid tumors and lymphomas. The deal reflects the continued build-out of cell therapy manufacturing capacity---a persistent bottleneck for the sector.
Endevica Bio / Kalohexis: Melanocortin System Spin-Out (March 19). Endevica Bio announced the spinout and launch of Kalohexis, a newly created biotechnology company advancing a portfolio of melanocortin system-targeting candidates for obesity and cancer cachexia. The pipeline includes 710GO, an oral dual MC3R/MC4R agonist entering Phase 1 for general obesity (first-in-human trial planned H1 2026), and mifomelatide, a dual MC3R/MC4R antagonist in Phase 2 for cancer cachexia in advanced colorectal cancer (NCT06937177, initiated Q2 2025). Preclinical studies of 710GO in non-human primates demonstrated 11.7% average weight loss over 13 weeks, with limited loss of lean body mass and no gastrointestinal side effects—a differentiating feature relative to GLP-1 receptor agonists. In combination with semaglutide, 710GO showed additive effects (6.5% weight loss over 19 days versus 3.0% for semaglutide alone). The Endevica leadership team will lead Kalohexis. The spin-out carries thematic significance in W12: it occurs in the same week as Rhythm Pharmaceuticals' EMANATE Phase 3 failure of setmelanotide (an MC4R agonist) across all four rare MC4R pathway substudies, and one day after Congruence Therapeutics dosed the first patient with CGX-926 (an MC4R corrector for genetic obesity). Together, these three events—EMANATE's failure, CGX-926's clinical entry, and Kalohexis's launch—frame the melanocortin system as a contested therapeutic frontier where mechanism-of-action differentiation (agonist vs. corrector vs. dual MC3R/MC4R modulation) will determine which approaches survive the translational gauntlet. For the cachexia program, mifomelatide addresses a genuinely unmet need: cancer cachexia has no approved pharmacological treatment and affects up to 80% of patients with advanced malignancies, contributing directly to mortality and limiting tolerance of anti-cancer therapies.
RenovoRx: ~$10 Million Private Placement (March 18). RenovoRx (Nasdaq: RNXT) announced a private placement of approximately 10.6 million shares at $0.938 per share with 50% warrant coverage, generating approximately $10 million in gross proceeds. Management and board participated at $1.029/share. Proceeds accelerate commercialization of the RenovoCath intra-arterial delivery platform and Phase III TIGeR-PaC enrollment for locally advanced pancreatic cancer.
Kupando: EUR 10 Million Series A Extension (mid-March). The Schönefeld, Germany-based clinical-stage biotech extended its Series A to EUR 23 million with a EUR 10 million raise co-led by Remiges Ventures and LifeCare Partners, with Brandenburg Kapital, HTGF, Ventura Biomed, and Carma Fund participating. Proceeds fund a Phase 1b study of KUP101 (TLR 4/7 agonist) in advanced solid tumors and preclinical infectious disease programs.
Surf Therapeutics: ~$6 Million Seed Extension (March 17). The Austin, TX clinical-stage company developing non-invasive ultrasound neuromodulation for immune-mediated diseases raised approximately $6 million from investors including SOSV, VVP Ignite, TMC Venture Fund, and angel investors including Mir Imran (Rani Therapeutics founder). Backed by positive first-in-human data showing significant TNF-alpha and IL-6 reductions in inflammatory arthritis patients.
Option Therapeutics: ~$20 Million IPO Filing Active (BioVie Spinout). Option Therapeutics (proposed Nasdaq: OPTN), a BioVie spinout, maintained an active amended S-1 filing during the W12 window targeting approximately $20 million (downsized from $25 million). Sole book-runner: ThinkEquity. Lead asset BIV201 (continuous-infusion terlipressin) has FDA Fast Track and Orphan Drug designations for liver cirrhosis complications. BioVie retains at least 60% ownership.
Embecta / Owen Mumford: Up to GBP 150 Million (~$200 Million) Acquisition (March 19). Embecta Corp. announced the acquisition of Owen Mumford Holdings for GBP 100 million upfront cash plus up to GBP 50 million in performance-based payments tied to Aidaptus autoinjector net sales over three years post-closing. Owen Mumford reported FY2025 revenue of GBP 69.4 million. While primarily a medtech transaction, the Aidaptus drug delivery platform serves pharmaceutical injectable delivery and is relevant to the GLP-1 device-drug combination product trend noted elsewhere in this term sheet.
Artelo Biosciences / Belfast Health and Social Care Trust (March 18). Investigator-initiated clinical study agreement for a pilot randomized crossover trial of ART27.13 (oral synthetic cannabinoid) in intraocular pressure/glaucoma, fully funded by Artelo.
Dyadic / IBT Bioservices: OEM Distribution Agreement (March 16). Dyadic (NASDAQ: DYAI) entered a commercial distribution agreement with Integrated Biotherapeutics for recombinant protein products for research applications.
Pfizer: PF-08046031 (SGN-CD228A) Phase 1 Discontinuation (March 20). Pfizer confirmed the discontinuation of PF-08046031, a CD228-targeting antibody-drug conjugate acquired in the $43 billion Seagen buyout, from its Phase 1 solid tumor trial (NCT06799533). The decision was made for "business reasons" with no safety concerns cited; only 11 participants had been enrolled before the trial was stopped. PF-08046031 was originally known as SGN-CD228A and targeted melanotransferrin, a cell-surface protein abundant on melanoma and other solid tumors. The termination is part of Pfizer's ongoing post-Seagen portfolio rationalization (11 programs cut in late 2024, 6 more in February 2026) and carries no external licensing or royalty implications---the asset was wholly Seagen-developed with no third-party licensor. Pfizer retains a related CD228-targeting bispecific (PF-08046049/SGN-BB228) still in Phase 1.
Gilead Sciences / Assembly Biosciences: HBV Option Decline (March 19). Assembly Biosciences disclosed that Gilead Sciences elected not to exercise or defer its option on ABI-4334, Assembly's next-generation capsid assembly modulator for chronic hepatitis B, under their October 2023 collaboration (which included a $100 million upfront payment). The economics Gilead walked away from are substantial: a $45 million opt-in fee, up to $330 million in regulatory and commercial milestones, tiered royalties from high single-digits to high teens (with rates depending on clinical stage at opt-in), and Assembly's retained 40% U.S. cost-profit share option (in lieu of U.S. milestones/royalties). The collaboration also included three $75 million extension payments at years 3, 5, and 7 shared across the partnership. Gilead retains a 29.9% equity stake in Assembly and its licensed herpesvirus programs (option exercised December 2025 for $35 million). Assembly retains sole worldwide rights to ABI-4334 and has initiated a structured partnering process, with $248.1 million in cash at year-end 2025 projecting runway into 2028. Phase 1b data had shown strong HBV DNA reductions (3.2 log10 IU/mL at 400 mg). For dealmakers, the rights reversion creates a meaningful out-licensing opportunity for a Phase 1b-stage HBV asset with disclosed royalty benchmarks (high single-digit to high teens)---and parallels the Astellas/CytomX termination pattern, where large pharma partners decline options on early-stage programs, returning assets to smaller companies with the opportunity to repartner at potentially higher valuations. For royalty investors specifically, the Assembly re-partnering process is worth monitoring: any new licensee would likely face royalty rate benchmarks established by the Gilead deal structure, making the high single-digit to high teens range a floor for market expectations.
Fauna Bio / Eli Lilly: Obesity Target Designation Milestone (March 19). Fauna Bio announced the designation of a new obesity drug target under its December 2023 discovery collaboration with Eli Lilly---a deal originally valued at up to $494 million in milestones plus royalties. The December 2023 agreement includes an undisclosed upfront cash payment plus an undisclosed equity investment from Lilly, with up to $494 million in aggregate milestone payments spanning preclinical, clinical, regulatory, and commercial milestones (breakdown across categories not disclosed), plus royalties on product sales at undisclosed rates. The target was identified using Fauna's Convergence AI platform, which analyzes genomic data from over 450 mammalian species (including hibernating ground squirrels) to identify metabolic resilience mechanisms. Lilly assumes responsibility for optimization and development. The milestone triggered an undisclosed payment---the first target designation under this collaboration. Fauna CEO Ashley Zehnder has described the upfront as "comparable to other early target stage discovery deals" and "sizable," suggesting the $494 million headline is in addition to the upfront and equity components. The Fauna Bio milestone adds to the W12 AI-pharma infrastructure theme alongside the Roche/NVIDIA AI factory, the IQVIA.ai platform launch, and the Basecamp Research Trillion Gene Atlas initiative.
Humacyte: $20 Million Registered Direct Offering (March 19). Humacyte (Nasdaq: HUMA) priced a registered direct offering of 25 million shares at $0.80 per share, raising $20 million in gross proceeds to fund commercialization of Symvess (bioengineered blood vessels for vascular trauma) and its Phase 3 hemodialysis vascular access program. Titan Partners (American Capital Partners) served as sole placement agent.
PharmaMar / Globant: AI Oncology Research Collaboration (March 19). PharmaMar (BME: PHM) partnered with IT services firm Globant to deploy a multi-agent AI system (Globant Enterprise AI) for cancer drug discovery, utilizing over 20 specialized AI agents across preclinical, clinical, regulatory, and commercial workflows. The system reviews 4,500+ research documents to prioritize treatment-indication combinations from 8,000+ possibilities, achieving >90% accuracy in complex data retrieval and a 15x reduction in time-to-insights. Financial terms were not disclosed.
Trinity Biotech / University at Buffalo: Sjogren's Syndrome Biomarker Collaboration (March 18). Trinity Biotech (Nasdaq: TRIB) announced a collaboration with the University at Buffalo to advance and commercialize proprietary biomarkers for earlier detection of Sjogren's Syndrome. Biomarkers are licensed from UB to Trinity's IMMCO Diagnostics subsidiary, with Trinity's NYSDOH-approved reference laboratory serving as the launch platform. Financial terms were not disclosed.
HCW Biologics / Beijing Trimmune Biotech: Exclusive Worldwide License for HCW11-006
On March 17, 2026, HCW Biologics (NASDAQ: HCWB) announced the receipt of full payment of the upfront license fee from Beijing Trimmune Biotech Co., Ltd. for an exclusive worldwide license for HCW11-006, a preclinical multi-functional fusion immunotherapeutic generated from HCW Biologics' proprietary TRBC (T-cell receptor beta chain constant region) drug discovery and development platform.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | HCW Biologics, Inc. (NASDAQ: HCWB; Miramar, FL) |
| Licensee | Beijing Trimmune Biotech Co., Ltd. (newly formed JV entity) |
| JV partners | WY Biotech Co., Ltd. (China; recombinant protein/gene/cell therapy) and HCW Biologics |
| JV investors | CITIC Medical Fund (multi-billion-dollar healthcare fund); TigerYeah Capital Fund of TigerMed (global CRO) |
| Asset | HCW11-006 (preclinical fusion immunotherapeutic; in vivo applications) |
| Territory | Exclusive worldwide |
| Upfront consideration | $7.0 million total: $3.5 million cash + $3.5 million transferable equity interest in Trimmune |
| Development milestones | Significant development milestone payments (amounts not disclosed) |
| Royalties | Double-digit royalties on future product sales |
| Transaction participation | Portion of proceeds from future transaction(s) involving the licensed molecule |
| Americas opt-in | HCW retains a payment-free, milestone-free, and royalty-free option to recapture all rights for U.S., Canada, Central America, and South America after conclusion of Phase 1 in China |
| Development responsibilities | Trimmune funds and conducts all Phase 1 clinical trial costs in China |
| Phase 1 timeline | First half of 2027 (solid tumors, China) |
| Additional option | Trimmune holds option to license exclusive Greater China rights to HCW9302 (HCW Biologics' clinical-stage IL-2 fusion for autoimmune diseases) |
| SEC filing | Form 8-K filed February 2026 (original JV announcement); payment confirmation March 17, 2026 |
Mechanism and Platform Context
HCW11-006 is a multi-functional fusion protein biologic designed to integrate functional domains of interleukin-12 (IL-12), interleukin-15 (IL-15), and a PD-L1 blocking component into a single engineered construct. The molecule is intended to simultaneously activate natural killer cells and T cells through cytokine receptor signaling while blocking the PD-1/PD-L1 immune checkpoint axis---combining immune stimulation and checkpoint inhibition in a single agent. HCW Biologics' TRBC platform has generated over 50 molecules, including HCW11-018b ("Big BiTE," a tetra-valent T-cell engager) and HCW11-040 (a pembrolizumab-based tetra-valent checkpoint inhibitor with TGF-beta neutralization), both in IND-enabling development.
The TRBC platform's modular scaffold is mechanistically distinct from conventional approaches in several respects: where most combination immunotherapy strategies require co-administration of separate agents (e.g., checkpoint inhibitor + cytokine), HCW11-006 consolidates multiple immune activation pathways into a single molecule---potentially simplifying manufacturing, dosing, and regulatory strategy while reducing combinatorial toxicity risks. Competitors in the multi-functional immunotherapy space include Sonnet BioTherapeutics (IL-12/IL-15 fusions), ImmunityBio (Anktiva, an IL-15-based agonist), and conditionally activated cytokine platforms from Werewolf Therapeutics.
Licensing and Royalty Implications
The HCW/Trimmune deal is notable for its structuring rather than its scale. At $7 million upfront, it is one of the smaller licensing transactions in the W12 window---but the deal architecture illustrates several patterns relevant to the broader licensing and royalty landscape:
Externalized clinical risk with retained optionality. By granting Trimmune an exclusive worldwide license while retaining a payment-free, milestone-free, royalty-free option to recapture Americas rights after Phase 1 completion in China, HCW Biologics has created a structure that externalizes all early-stage clinical cost and execution risk to the China-backed JV while preserving full upside in the largest pharmaceutical market. This "free option" structure---where the licensor gets Phase 1 data generated at the licensee's expense, then decides whether to reclaim territorial rights with zero incremental cost---is an increasingly common motif in U.S.-to-China-JV licensing deals.
CRO investor as strategic capital. TigerYeah Capital Fund, the venture arm of TigerMed---one of the world's largest clinical contract research organizations---as a Trimmune investor creates a vertically integrated development pathway: the CRO that will likely execute the Phase 1 trial in China is also an equity investor in the entity funding it. This mirrors the DaVita/U.S. Renal Care investor-channel alignment in the R1 Therapeutics deal, where the end-users of the product are also financing its development.
Dual-asset optionality. The inclusion of an option for Trimmune to license Greater China rights to HCW9302 (the clinical-stage IL-2 fusion for autoimmune diseases currently in Phase 1 for alopecia areata) creates a multi-asset relationship that could expand Trimmune's pipeline beyond oncology---and generate additional payments for HCW Biologics.
For royalty investors, the double-digit royalty on future net sales and the transaction-proceeds participation rights create layered economics that could become material if HCW11-006 or its platform derivatives reach commercialization. The preclinical stage and single-molecule scope limit near-term royalty relevance, but the TRBC platform's modularity and the growing institutional interest in multi-functional immunotherapeutics make HCW Biologics a platform-level watchlist item.
Sandoz and Samsung Bioepis: Global Biosimilar Partnership Expansion
On March 18, 2026, Samsung Bioepis Co., Ltd. and Sandoz (SIX: SDZ) announced a development, commercialization, and license agreement covering up to five next-generation biosimilar candidates, headlined by SB36, a biosimilar referencing Takeda's Entyvio (vedolizumab).
Deal Structure
| Term | Detail |
|---|---|
| Developer | Samsung Bioepis Co., Ltd. (Incheon, South Korea) |
| Commercialization partner | Sandoz (Basel, Switzerland; SIX: SDZ) |
| Assets | Up to five next-generation biosimilar candidates, led by SB36 (vedolizumab biosimilar) |
| Samsung Bioepis responsibilities | Development, regulatory registration, manufacturing |
| Sandoz responsibilities | Global commercialization |
| Excluded territories | China, Hong Kong, Taiwan, Macau, South Korea |
| Financial terms | Not publicly disclosed |
Strategic Context
The agreement expands Sandoz's total biosimilar pipeline to approximately 32 assets, reinforcing its position as the industry's leading biosimilar company. Entyvio generated approximately $8.5 billion in 2025 global sales for Takeda, making it one of the largest biologic revenue streams currently lacking a biosimilar competitor. The Sandoz/Samsung Bioepis partnership already encompasses multiple marketed products and represents one of the most commercially significant biosimilar development relationships in the industry.
For royalty and licensing analysts, the deal is structurally notable: while financial terms were not disclosed, the partnership model---where Samsung Bioepis bears development and manufacturing costs while Sandoz manages global commercial execution---creates a layered economic structure that typically includes profit-sharing, milestone payments, or tiered royalties on net sales in the licensed territories. For context, the prior Biogen/Samsung Bioepis JV operated under a 50/50 profit-sharing model (Biogen reported approximately $56 million per quarter in collaboration profit-sharing expense in 2024), and Biogen's 2019 ophthalmology biosimilar expansion paid $100 million upfront plus up to $210 million in milestones—benchmarks that suggest the Sandoz deal likely involves substantial but undisclosed profit-sharing economics. Separately, Sandoz's 2025 collaboration with Evotec for up to 10 biosimilar molecules was structured at potentially over $650 million plus royalties, providing a further comparator for multi-asset biosimilar partnership valuations.
Samsung Bioepis / Epis NexLab / G2GBIO: Long-Acting Semaglutide Research Collaboration and License
On March 15, 2026, Samsung Bioepis Co., Ltd. and Epis NexLab announced a research collaboration and license agreement with G2GBIO, a South Korean biotechnology company specializing in microsphere-based drug delivery technology, to develop novel assets including a long-acting semaglutide formulation.
Deal Structure
| Term | Detail |
|---|---|
| Licensee | Samsung Bioepis Co., Ltd. (Incheon, South Korea) |
| Co-developer | Epis NexLab |
| Licensor / technology partner | G2GBIO (South Korea) |
| Licensed asset | Long-acting semaglutide using G2GBIO's microsphere delivery technology |
| Additional rights | Option to license one additional asset; right of first negotiation for three further assets |
| Financial terms | Upfront payment confirmed but amount confidential; milestone-based structure confirmed but amounts confidential; Samsung Bioepis bears all global development costs for both drug candidates |
| Convertible bond investment | KRW 20 billion (~$13-14.5 million) by Samsung Epis Holdings in G2GBIO (0% interest, 2% yield to maturity, March 2031 maturity) |
Strategic Context
The deal is notable for its timing within the W12 GLP-1/obesity investment cycle. In the same week, Structure Therapeutics reported 16.3% placebo-adjusted weight loss at 44 weeks with oral aleniglipron, ProLynx closed a $70 million Series A for longer-acting incretin therapies targeting monthly dosing, Fauna Bio hit its first target designation milestone under the $494 million Lilly obesity collaboration, and Endevica Bio spun out Kalohexis with 710GO (an oral MC3R/MC4R agonist showing additive effects with semaglutide). The Samsung Bioepis/G2GBIO collaboration adds a delivery technology dimension to this cluster: a long-acting semaglutide formulation using microsphere encapsulation could extend dosing intervals beyond the current weekly (subcutaneous) or daily (oral) regimens, addressing the compliance and convenience drivers that are reshaping the competitive landscape in GLP-1 therapeutics.
For Samsung Bioepis, the deal also represents a strategic expansion beyond biosimilars into novel formulation development---a diversification consistent with the company's simultaneous expansion of its Sandoz biosimilar partnership (detailed above) and a signal that Samsung Bioepis is positioning to compete in both the reference biologics and next-generation formulation markets.
Elaris FlexCo and Valneva: Exclusive Global License for VLA84 C. difficile Vaccine Technology
On March 18, 2026, Elaris FlexCo announced an exclusive global license agreement with Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) for technology related to Valneva's Clostridioides difficile vaccine candidate, VLA84. Under the agreement, Elaris obtains an exclusive global license to Valneva's antigen technology targeting C. difficile, with plans to advance a next-generation vaccine program incorporating additional proprietary components designed to broaden protective immune responses.
Mechanism and Clinical History
VLA84 is a recombinant fusion protein comprising truncated cell-binding domains of C. difficile Toxin A (TcdA) and Toxin B (TcdB). Unlike toxoid-based approaches that use chemically inactivated full-length toxins (as pursued by Sanofi and Pfizer in their respective clinical programs), VLA84's single fusion protein design is anticipated to simplify manufacturing while retaining immunogenicity against both major virulence factors. In a Phase 1 trial (NCT01296386) involving 141 healthy adult and elderly volunteers, VLA84 was safe, well tolerated, and highly immunogenic, inducing high IgG antibody titers against both Toxin A and Toxin B with functional neutralization confirmed in a T84 toxin neutralization assay. A Phase 2 dose-confirmation study (NCT02316470) in 500 healthy adults aged 50 and older was completed, but Valneva did not advance VLA84 into later-stage development---making the out-licensing to Elaris a strategic divestiture of a validated but deprioritized asset.
Deal Structure
| Term | Detail |
|---|---|
| Licensor | Valneva SE (Lyon, France; Nasdaq: VALN) |
| Licensee | Elaris FlexCo (Vienna, Austria) |
| Asset | VLA84 antigen technology for C. difficile vaccine |
| Territory | Exclusive global |
| Milestones | Two development-related milestone payments; multiple regulatory approval and commercialization milestones |
| Royalties | Royalties on future net sales |
| Development plan | IND-enabling development with clinical studies targeted around 2027 |
| Elaris leadership | Jason Golan (CEO, Co-Founder); Christian Taucher (Co-Founder) |
Financial terms were not quantified in the announcement, but Valneva's 2025 annual report (filed March 18, 2026) describes the agreement as including two development-related milestone payments, multiple milestone payments tied to regulatory approval and commercialization across global markets, and royalties on future net sales. Valneva bears no further development costs. For the royalty community, the Elaris/Valneva deal creates a clean out-license structure: milestones plus royalties, with all downstream development and commercialization risk borne by Elaris---a pattern consistent with Valneva's broader strategy of divesting non-core pipeline assets (the company is concentrating resources on its Lyme disease program VLA15 with Pfizer and its Shigella vaccine S4V2) while retaining residual economic participation through royalty and milestone streams.
Strategic and Market Context
Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired diarrhea worldwide, causing approximately 500,000 infections and 29,000 deaths annually in the United States alone, with 170,000 infections annually in Europe. Despite the substantial disease burden, no vaccine against C. difficile is currently approved. The competitive landscape has narrowed significantly: Sanofi's toxoid vaccine (ACAM-CDIFF) failed in a Phase 3 trial (CDIFFENSE, 9,302 patients), and Pfizer's toxoid candidate (PF-06425090) has not advanced to registration. The failure of both major pharma-sponsored programs leaves the CDI vaccine field without a late-stage contender---creating an opportunity for differentiated approaches.
Elaris is a Vienna BioCenter-based biotech startup co-founded by two former Valneva employees, positioning the deal as a spin-out of deprioritized Valneva vaccine technology into a focused, mission-driven vehicle. Elaris plans to build on VLA84's antigen technology with additional proprietary components to broaden immune protection---potentially addressing the limitation of toxin-only approaches by incorporating antigens targeting colonization or spore formation. The deal reflects a broader pattern in the vaccine industry: large specialty vaccine companies (Valneva, which is concentrating resources on its Lyme disease program VLA15 with Pfizer and its Shigella vaccine S4V2) divesting non-core assets to smaller, focused entities with the flexibility to pursue IND-enabling and early clinical development.
For royalty investors, the Elaris/Valneva deal creates a future royalty stream contingent on Elaris's ability to fund and execute a clinical development program in a field where two major competitors have already failed---a high-risk, high-reward proposition in a large unmet need indication.
Nanobiotix / Johnson & Johnson: Phase 3 Licensing Deal Amendment
On March 17, 2026, Nanobiotix (Euronext: NANO; Nasdaq: NBTX) referenced the March 2025 amendment to its 2023 licensing agreement with Johnson & Johnson for NBTXR3/JNJ-1900, a first-in-class radioenhancer in Phase 3 for locally advanced head and neck squamous cell carcinoma, in its latest corporate update. The amendment removed Nanobiotix's obligation to co-fund the Phase 3 trial, with J&J now bearing full development costs while retaining global commercial rights. The original deal included a $30 million upfront payment and up to approximately $2.6-2.7 billion in regulatory, sales, and commercial milestones (reduced slightly from the original ~$2.7 billion by select milestone adjustments in the amendment), plus tiered double-digit royalties in the low teens to low twenties on global net sales (Asia territory royalties described separately as tiered, low double-digit). The restructuring extends Nanobiotix's cash runway into mid-2026 and represents a meaningful reallocation of Phase 3 risk from the licensor to the licensee---a deal amendment pattern worth monitoring as clinical-stage biotechs increasingly seek to preserve capital by renegotiating co-funding obligations with larger partners.
CounterX Therapeutics: Opioid Abuse Treatment License
On approximately March 17, 2026, Seattle-based CounterX Therapeutics secured an exclusive license from the University of Washington and University of Minnesota for patents targeting opioid abuse, advancing its lead drug CTRX-101 (injectable anti-fentanyl antibody) toward clinical trials. The licensed patents also cover vaccine candidates for relapse prevention in opioid use disorder. State Attorneys General / Bausch Health: Antitrust Settlement. State attorneys general reached a $17.85 million settlement with Bausch Health US, LLC, Bausch Health Americas, Inc. ($4.08 million), and Lannett Company, Inc. ($13.77 million) over conspiracies to inflate generic drug prices. The settlement was originally announced on February 2, 2026, with preliminary court approval on February 28. While not a licensing or investment transaction, antitrust enforcement actions in the pharmaceutical sector serve as a reminder of the regulatory and legal risk environment that affects deal structuring, pricing strategy, and corporate valuation.
Indivior: $500 Million Convertible Senior Notes (settled March 17). Indivior (Nasdaq: INDV), the maker of SUBLOCADE (extended-release buprenorphine), priced a $450 million offering of 0.625% convertible senior notes due March 2031 (upsized from $400 million), plus a $50 million overallotment exercised at settlement, bringing total proceeds to $500 million. The conversion price was approximately $41.66 per share (~35% premium). Approximately $75 million funded concurrent share repurchases of ~2.4 million shares. The Indivior convertible is the second-largest convertible note offering in the W12 window after the CRISPR Therapeutics $600 million deal, and adds to the non-dilutive capital theme running throughout the week.
AstraZeneca: Shanghai Cell Therapy and Guangzhou Radioconjugate Manufacturing Investments (March 19). AstraZeneca announced the construction of a commercial-scale CAR-T manufacturing and supply base in Shanghai's Lingang Free Trade Zone, alongside an innovation center in Zhangjiang for viral vector and plasmid development. The company also announced a radioconjugate drug production base in Guangzhou. These investments support the development of autologous CAR-T therapies including AZD0120 (a BCMA/CD19 dual-targeting candidate from the Gracell acquisition) and are part of AstraZeneca's $15 billion China investment pledge through 2030. The manufacturing expansion directly complements the TerraPower actinium-225 facility and Bicycle Therapeutics' radiopharmaceutical supply chain initiatives also announced in W12.
Novo Nordisk: Semaglutide India Patent Expiry (March 20). The semaglutide patent expired in India during W12, triggering the entry of 40+ generic manufacturers with 50+ branded generics. Natco Pharma launched Semanat/Semafull at approximately 90% below innovator pricing, while Eris Lifesciences launched at INR 220 per shot. India's GLP-1 market, estimated at INR 1,000-1,200 crore in 2025, is projected to grow to INR 4,500-5,000 crore by 2030. While not a deal event per se, the patent expiry creates the first large-scale generic GLP-1 market globally and has implications for Novo Nordisk's international pricing strategy at the same time the company is launching Wegovy HD in the U.S.
Sun Pharma: ILUMYA (Tildrakizumab) sBLA Accepted by FDA (March 16). Sun Pharmaceutical Industries announced FDA acceptance of a supplemental BLA for ILUMYA (tildrakizumab), an anti-IL-23p19 monoclonal antibody, for the treatment of active psoriatic arthritis in adults, based on the Phase 3 INSPIRE-1 and INSPIRE-2 trials. The PDUFA date is October 29, 2026. The psoriatic arthritis expansion is competitively relevant to the J&J/Protagonist ICOTYDE approval—both target the IL-23 pathway in inflammatory diseases, albeit through different modalities (injectable biologic vs. oral peptide).
BioMap: Confidential Hong Kong IPO Filing (~March 16-17). BioMap, a Baidu-backed AI biotech co-founded by CEO Robin Li, filed confidentially for a Hong Kong Stock Exchange listing that could raise several hundred million dollars. BioMap's xTrimo V4 foundation model (268 billion parameters) has been validated in 60+ projects serving 800+ global institutions. CICC, Morgan Stanley, and UBS are advising. The filing follows Insilico Medicine's successful December 2025 HK IPO ($337 million, stock surged 130%) and adds to the W12 AI-pharma infrastructure theme alongside the Roche/NVIDIA AI factory and the IQVIA.ai platform launch.
Daré Bioscience: NIH Funding Extension (March 16). Daré Bioscience received an approximately $2 million NIH funding extension for DARE-PTB1, a novel intravaginal ring for the prevention of preterm birth, extending the grant through November 2026.
Conference-Stage Collaborations
Photocure and medac: Bladder Cancer Care at EAU 2026
On March 16, 2026, Photocure ASA (OSE: PHO) announced two "trial in progress" presentations at the 2026 European Association of Urology (EAU) congress in London featuring its Hexvix (hexaminolevulinate HCl) product for improved detection of bladder tumors. The EAU scientific program prominently featured Hexvix and the blue light cystoscopy (BLC) procedure in which it is used.
During the EAU Congress on March 13, Photocure and medac co-hosted a scientific event titled "Optimising Care in Bladder Cancer," moderated by Mr. John McGrath (Consultant Urological Surgeon, North Bristol Trust). The session brought together leading clinicians to discuss current challenges and advances in bladder cancer management, with a focus on improving patient pathways and outcomes for women.
The two featured trials---CUT-less (investigating whether second-look transurethral resection can be safely omitted by combining MRI staging with BLC-guided TURBT) and a second trial addressing data gaps in the diagnostic pathway---reflect the broader evolution of Hexvix's clinical evidence base from tumor detection toward treatment decision optimization.
Hexvix/Cysview is currently the only approved optical imaging agent for diagnosing and surgical management of bladder cancer worldwide. Photocure commercializes the product directly in the US (as Cysview) and Europe (as Hexvix) and has strategic licensing partnerships for China (Asieris Pharmaceuticals, which holds exclusive commercialization rights in China), Chile, Australia, New Zealand, and Israel---a hub-and-spoke licensing model that generates royalty and milestone income from multiple geographies while Photocure retains direct commercial control in its largest markets.
Photocure/Asieris China License Economics
The January 2021 license agreement granting Asieris exclusive rights to register and commercialize Hexvix in mainland China and Taiwan includes the following disclosed terms:
| Term | Detail |
|---|---|
| Upfront payment | USD 750,000 |
| Regulatory milestones | Up to USD 1.4 million (tied to China NMPA and Taiwan market approvals) |
| Product supply | Photocure manufactures and supplies at a markup (percentage undisclosed) |
| Royalties | Royalties on product net sales in China and Taiwan (rate undisclosed) |
| Cost allocation | Asieris funds all regulatory, clinical, and commercialization costs in the licensed territories |
Photocure's 2022 annual report confirmed NOK 6.4 million in signing revenues from Asieris in 2021, consistent with the $750,000 upfront. In November 2024, Asieris obtained NMPA marketing approval for Hexvix in China, likely triggering a portion of the $1.4 million regulatory milestones. Note that Photocure's separate global license with Asieris for Cevira (photodynamic therapy for cervical precancer, signed 2019) carries substantially larger terms: a $5 million signing fee, up to $250 million in milestones, and 10-20% tiered royalties---terms that should not be conflated with the smaller Hexvix China deal.
Corporate and Financial Reporting
Idorsia: CEO Departure and Leadership Transition
On March 16, 2026, Idorsia Ltd (SIX: IDIA) announced that CEO Srishti Gupta, M.D., had stepped down after less than nine months in the role, also departing the Board of Directors. Founder and Chairman Jean-Paul Clozel, M.D., assumed interim CEO responsibilities while the board initiates a search for a permanent successor with "extensive pharmaceutical leadership experience and strong commercial expertise."
The abrupt departure---Gupta had been appointed only in July 2025---sent Idorsia shares down more than 10% and raises questions about strategic direction at the Basel-headquartered biotech, which markets insomnia treatment Quviviq (daridorexant) and hypertension treatment Tryvio. The company reported FY2025 revenues of CHF 221 million (approximately $265 million), nearly double the prior year, with operating losses narrowing significantly from CHF 232 million to CHF 33 million. For the broader European biotech ecosystem, the Idorsia transition is a reminder that leadership stability remains a critical factor in commercial-stage companies navigating the transition from pipeline-driven to revenue-driven valuation.
GenScript Biotech: FY2025 Results Cross $500 Million Revenue Milestone
On March 15, 2026, GenScript Biotech (SEHK: 1548) reported FY2025 results with its Life Science Group generating $522.1 million in revenue, a 14.8% year-over-year increase that surpassed the $500 million milestone for the first time. The company is targeting 60% AI-driven automation across global production operations by end-2026, reflecting the broader trend of AI integration into life sciences services and contract research.
Novo Nordisk: Share Repurchase Program Update
On March 16, 2026, Novo Nordisk disclosed the repurchase of 6.58 million B shares at an average price of DKK 271.14 per share (DKK 1.78 billion total) under its DKK 15 billion, 12-month share repurchase program. The ongoing buyback reflects Novo Nordisk's strong cash generation from the GLP-1 franchise amid continued global demand for semaglutide.
XOMA Royalty: FY2025 Earnings and Portfolio Expansion (March 18)
On March 18, 2026, XOMA Royalty (NASDAQ: XOMA) reported its fourth quarter and full year 2025 financial results, marking a milestone year for the biotech royalty aggregator. XOMA's pure-play royalty model---acquiring economic interests in clinical-stage and commercial therapeutic candidates---makes its earnings a useful barometer for the health of the pharmaceutical royalty market.
FY2025 Financial Highlights
| Metric | FY2025 | FY2024 | Change |
|---|---|---|---|
| Total cash receipts | $50.5 million | $46.3 million | +9% |
| Royalties and commercial payments | $33.6 million | $20.0 million | +68% |
| Milestone payments and fees | $16.9 million | $26.3 million | -36% |
| Cash and cash equivalents (Dec. 31) | $133.7 million (incl. $50.8M restricted) | $106.4 million | +26% |
| Share repurchases | $16.0 million (648,048 shares) | --- | --- |
The 68% year-over-year growth in royalty income---driven primarily by Roche/Genentech's Vabysmo (faricimab) and Day One Biopharmaceuticals' Ojemda (tovorafenib)---is the headline figure. XOMA achieved positive cash flow from operations for the first time on a consistent basis, validating the biotech royalty aggregator model at a scale below the large-cap royalty companies (Royalty Pharma, RPRX). CEO Owen Hughes noted that the company added 22 assets and two platform technologies over the past year through seven acquisitions and a restructured Takeda collaboration that secured royalty and milestone rights across nine development-stage assets. The Pulmokine acquisition (November 2024, $20 million), which secured low-to-mid single-digit net royalties and up to $25 million in milestones on Gossamer Bio's seralutinib for pulmonary arterial hypertension, has been materially impaired by the Phase 3 PROSERA failure (detailed above in the Gossamer Bio section)---illustrating the binary risk inherent in Phase 3-stage royalty acquisitions.
Portfolio and Pipeline
XOMA's portfolio now includes 14 programs in registrational studies, with several key 2026 catalysts: Phase 2b data from volixibat in primary sclerosing cholangitis (Q2 2026), Phase 3 data from ersodetug in tumor hyperinsulinism (H2 2026), potential EMA marketing authorization decisions for Ojemda and Miplyffa (arimoclomol), and regulatory updates on seralutinib in pulmonary arterial hypertension. The February 2026 completion of the Generation Bio acquisition further expanded the portfolio, adding to a run of whole-company acquisitions (Kinnate Biopharma, Pulmokine, Mural Oncology, LAVA Therapeutics) that has transformed XOMA from a single-asset royalty holder into a diversified portfolio company.
Janssen/TREMFYA Litigation
Notably, XOMA disclosed ongoing litigation against Janssen Biotech, Inc., asserting claims for breach of contract and unjust enrichment arising from Janssen's alleged unauthorized use of XOMA's intellectual property in the commercialization of TREMFYA (guselkumab). G&A expenses for FY2025 included approximately $1.1 million in legal costs associated with this litigation. TREMFYA generated approximately $4.2 billion in 2025 sales for Johnson & Johnson, making the outcome of this dispute potentially material to XOMA's economics.
Implications for the Royalty Market
XOMA's FY2025 results carry broader implications for the pharmaceutical royalty market. The demonstration that a sub-$500 million market cap royalty aggregator can achieve positive operating cash flow from a diversified portfolio of commercial royalties validates a tier of the market below Royalty Pharma ($20+ billion market cap) and DRI Healthcare ($1+ billion). For Capital for Cures and other participants in the royalty ecosystem, the XOMA model---particularly its willingness to acquire whole companies to extract royalty economics and its use of platform technology collaborations as a sourcing channel---represents an increasingly proven playbook for building royalty portfolios at scale.
Academic and Translational Research Collaborations
Southern Cross University and Melbourne Integrative Oncology Group
Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) announced an AUD $1 million collaborative research program in oncology. While the partnership is modest in scale relative to the multi-billion dollar licensing agreements that dominate the term sheet, it represents the type of early-stage, investigator-initiated collaboration that increasingly feeds the translational pipeline in Australia's growing life sciences ecosystem.
Upcoming Catalysts: PDUFA Dates, Conference Calendar, and Regulatory Environment
Stifel 2026 Virtual CNS Forum (March 17-18)
The Stifel 2026 Virtual CNS Forum (March 17-18) featured presentations from over a dozen CNS-focused companies, several with near-term catalysts directly relevant to deal activity:
ACADIA Pharmaceuticals provided updates on its Phase 3 ACP-204 trial in Alzheimer's disease psychosis, with data readout expected August-October 2026, and discussed advancement of ACP-211 (deuterated R-ketamine) for major depressive disorder. Rapport Therapeutics disclosed an accelerated Phase 3 timeline for RAP-219 in epilepsy, now targeting Q2 2026. Voyager Therapeutics described 2026 as its "year of tau," with tau PET imaging data expected by year-end. Immunic presented strategic insights on vidofludimus calcium, with Phase 3 multiple sclerosis data expected at year-end. VistaGen discussed fasedienol, with PALISADE-4 results expected H1 2026. Additional presenters included Alto Neuroscience, Neurocrine Biosciences, Alkermes (featuring orexin program insights), Compass Pathways, Minerva Neurosciences, and Acumen Pharmaceuticals.
Federal Court Blocks Kennedy ACIP Vaccine Overhaul (March 16)
On March 16, 2026, U.S. District Judge Brian Murphy issued a preliminary injunction staying the CDC's January 2026 memo that had reduced recommended childhood vaccinations from 17 to 11 diseases, blocking 13 of 15 Kennedy ACIP appointees as "distinctly unqualified," and invalidating all votes taken by the reconstituted ACIP. The ruling has significant implications for vaccine manufacturers and the broader pharmaceutical supply chain. Moderna rose 1.4% on the news; Pfizer, Merck, and GSK also traded modestly higher. For dealmakers in the vaccine space, the ACIP ruling creates near-term regulatory uncertainty that could affect both the Elaris/Valneva C. difficile vaccine deal (where ACIP recommendation would eventually be required for broad commercial uptake) and the broader vaccine partnering environment.
MFN Pricing and Its Impact on Licensing Deal Structures
On March 17, 2026, Endpoints News reported that the biopharma industry is actively exploring creative modifications to licensing deal structures to cushion the impact of the Trump administration's Most Favored Nation (MFN) pricing agreements on U.S. drug pricing economics.
The MFN framework---under which 14 of the 17 largest pharmaceutical companies have now signed voluntary pricing agreements with the White House---directly affects deal economics for licensing, royalty, and M&A transactions. For licensors receiving royalties on net sales, MFN-driven price compression in U.S. Medicare and Medicaid channels reduces the revenue base on which royalties are calculated. For acquirers underwriting milestone-heavy deals, the uncertainty around future U.S. net pricing requires wider scenario ranges in valuation models. And for companies structuring new licensing agreements, contract provisions around pricing risk allocation, channel-specific carve-outs, and MFN adjustment mechanisms are becoming standard due diligence items. Separately, STAT News reported that the White House is actively working with Congress to codify voluntary MFN agreements into law, while ten midsize biotechs---including ACADIA, Madrigal, and Travere---formed the Midsized Biotech Alliance of America (MBAA) to push back against MFN policies they argue would disproportionately harm smaller companies' ability to fund innovation.
The practical implication for the deals covered in this term sheet is real. The R1/Alebund deal for AP306, with its tiered low double-digit royalties on ex-China net sales, is insulated from MFN exposure by its dialysis-clinic distribution model (where Medicare Part B reimbursement is the dominant payer). In contrast, the AbbVie/Aldeyra reproxalap profit-sharing structure---with its 60/40 U.S. split---would have been directly exposed to MFN-driven net price compression in the dry eye market's significant Medicare Part D and commercial channels, had approval been obtained.
Near-Term Regulatory Dates and Conferences
Several near-term regulatory dates and events create catalysts for deal activity through the end of March and into early April:
| Date | Company | Asset | Indication |
|---|---|---|---|
| ~~March 20~~ March 19 | Rhythm Pharmaceuticals | Imcivree (setmelanotide) | Approved for acquired hypothalamic obesity (one day ahead of PDUFA) |
| ~~March 19~~ March 19 | Novo Nordisk | Wegovy HD (semaglutide 7.2 mg) | Approved for weight management (54-day CNPV review) |
| ~~March 24~~ March 19 | GSK | Lynavoy (linerixibat) | Approved for cholestatic pruritus in PBC (ahead of PDUFA) |
| March 28 | Rocket Pharmaceuticals | Kresladi (vael-cel) | Gene therapy for LAD-I |
| ~March 29 | Lantheus | LNTH-2501 | PET imaging kit |
| May 24 | Eisai/Biogen | Lecanemab SC initiation | sBLA PDUFA |
| October 29 | Sun Pharma | ILUMYA (tildrakizumab) | sBLA for psoriatic arthritis |
BIO-Europe Spring 2026 opens March 23 in Lisbon and typically triggers a wave of licensing and partnering deal announcements. The Stifel CNS Forum (March 17-18) featured presentations from Neurocrine Biosciences, Compass Pathways, Korsana Biosciences, and Vistagen.
Conclusion
W12 carried more strategic weight than its conference-dominated opening suggested. Over $9 billion in financing, M&A, and deal activity across 40+ transactions landed in a single week---anchored by the Novartis/Synnovation $3 billion PI3Ka acquisition, the Collegium/Corium $785 million AZSTARYS deal, $1.3 billion in Blackstone-led debt for Paratek-Radius, and $750 million in Blue Owl credit for TG Therapeutics.
Five themes define the week for dealmakers and royalty investors:
Royalty streams activated and extinguished. The J&J/Protagonist ICOTYDE approval triggered a $50 million milestone and activated a 6-10% tiered royalty on a projected $5-10 billion franchise—the week's most consequential licensing event. The Collegium/Corium AZSTARYS acquisition and Zevra/Commave SDX sale both involved pre-transaction royalty buyouts, signaling that acquirers are paying premiums for clean IP structures. The Xtandi upstream royalty (4% to Royalty Pharma, ~$180 million annually) gains further relevance as TALAPRO-3 data support label expansion into earlier prostate cancer.
Non-dilutive capital at scale. Over $3.6 billion in private credit deployed across revenue-linked debt (Blackstone, Blue Owl), pre-commercial lending (Pharmakon/Zenas), and GP-led secondaries (QHP/Azurity)---establishing pharmaceutical-grade private credit as a primary capital source competing with royalty financing.
Clinical catalysts compress the data-to-deal pipeline. Wegovy HD approved in 54 days under the CNPV pilot. Retatrutide's first Phase 3 win positions a potential tirzepatide successor. Pfizer's TALAPRO-3 and atirmociclib deliver twin oncology wins. Aspen's 12-month iPSC Parkinson's data represent a cell therapy inflection point. On the setback side, Rhythm's EMANATE failure, Roche's emugrobart discontinuation, and Aldeyra's third CRL each eliminated or deferred material royalty and milestone economics.
AI-pharma infrastructure reaches enterprise scale. Roche's 3,500+ Blackwell GPU deployment, Lilly's LillyPod, IQVIA's 150-agent agentic platform, and TerraPower's $450 million actinium-225 facility are not incremental investments---they are strategic bets that the next generation of therapeutics will be designed and manufactured through computational and nuclear infrastructure.
MFN pricing reshapes deal structuring. With 14 of 17 major pharma companies signed to voluntary MFN agreements and legislative codification under discussion, royalty economics, milestone triggers, and net sales projections face structural compression. Every licensing deal under construction now requires MFN scenario analysis.
BIO-Europe Spring 2026 opens in Lisbon on March 23. The dealmakers paying attention at conferences today are the ones signing term sheets tomorrow.
The information provided in this report is for informational purposes only. The author is not a lawyer, financial adviser, or investment professional. Nothing in this publication constitutes investment advice, legal advice, or a recommendation to buy or sell any security. Readers should conduct their own due diligence and consult qualified professionals before making any investment or business decisions.
Member discussion